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Inflammatory Bowel Diseases, Crohn's Disease and Ulcerative colitis, are 
idiopathic chronic conditions with multifactorial determinants. In general, terms, 
intestinal inflammation results from abnormal host-microbe interactions. Alterations 
in homeostasis involve host genetic factors, environmental cues and unique 
luminal microbial niches. We have examined the coordinated expressions of 
several molecular targets relevant to the mucosal immune system and identified 
signature biomarkers of IBD. Qualitative and q uantitative changes in the 
composition of microbiota can be related to unique immuno-phenotypes. This in 
turn can have more systemic effects that involve energy metabolism. Adiponectin, 
an adipose tissue derived adipokine, can restore cellular ATP levels and f ulfills 
innate immune functions. We have concluded that IBD might represent a state of 
adiponectin resistance relating to chronic inflammation and obesity status.  
Lastly we hypothesized that activation of xenobiotic pathway (AHR-aryl 
hydrocarbon receptor) can further modulate host immune and metabolic 
responses, and t hus contribute to IBD phenotypes. We found that IBD is 
associated with robust mucosal, aryl hydrocarbon receptor pathway and related to 
proinflammatory cytokine secretion. We conclude that IBD heterogeneity is 
reflected through distinct immunophenotypes. Furthermore, environmental cues 
that involve the AhR receptor and adipose tissue derived adiponectin are 
important regulators of the inflammatory process in IBD. 
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Chapter 1  
Introduction: 
          Crohn's Disease (CD) and Ulcerative Colitis (UC) are chronic intestinal 
disorders known as idiopathic inflammatory bowel diseases (IBD)1. IBD affects 
approximately 1.4 million Americans with a peak onset occurring at 15-30 years 
of age.  The development of CD and UC requires a genetic predisposition, a 
dysregulated immune response and an environmental trigger. Candidate genes 
include those that regulate innate immunity and epithelial barrier function 2-5 
(Figure 1.1). Additional genetic studies have revealed that gene products 
involved in the elimination of endogenous small organic cations, drugs and 
environmental toxins are linked to CD and UC etiology 6-8 (Figure 1.1).          
           Lifestyle choices such as diet are thought to contribute to CD and UC by 
altering the commensal flora (prebiotics) or promoting obesity related 
inflammatory responses 9 (Figure 1.1).  Thus, the interactions between genetic 
and environmental factors will shape the gut epithelial-innate immune interface 
and lead to unique phenotypes in patients with Inflammatory Bowel Diseases. 
Current CD therapies are rather broad in action and not particularly focused on 
patient characteristics. Understanding the contribution of host and environmental 
factors will promote individualized management of this heterogeneous patient 
population. 
          The intestinal barrier is a dynamic multilayered structure that consists of 
bacterial biofilm, mucus, epithelium cells and innate immune cells. Dysfunction of 
this complex barrier precedes the development of inflammation in patients with 
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Crohn's Disease 10 , as well as established animal models of Inflammatory Bowel 
Diseases 11.  The intestinal barrier must balance the need for selective 
permeability of nutrients with protection form microbial invasion. This daunting 
task is accomplished by physical means such as tight junction proteins and 
mucus production on one hand and innate immune exclusion mechanisms on the 
other hand.  
          Epithelial cells interact with luminal microbial antigens though specialized 
extracellular TLR receptors (toll-like receptors) and intracellular NLR (NOD-like 
receptors)12. Downstream signaling through these receptors promotes the 
production of antimicrobial peptides (defensins and cryptidins) and microbial 
antigen presentation through upregulation of MHC molecules (major 
histocompatibility complex). NOD2/Card15 receptor (Nucleotide binding 
Oligomerization Domanin2/Caspase activating recruiting Domain 15 receptor) 
mutations and defective HBD (human β-defensin) production have been found in 
IBD-Crohn's Disease patients13. Polymorphisms of NOD2/Card15 gene are 
believed to alter Paneth cell function and thus explain the impairment in 
antimicrobial peptides. Mechanistically, NOD2 senses the intracellular bacterial 
antigen MDP (muramyl dipeptide) and recruits adaptor proteins with subsequent 
activation of the NF-κB pathway. This pathway commonly results in 
transcriptional upregulation of proinflammatory genes. Therefore, defective 
NOD2 signaling in Inflammatory Bowel Diseases patients seemed, at first 
counterintuitive.  
          Recent studies addressing the role of epithelial NF-κB pathway ,have 
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furthered our understanding of the pathophysiology of Inflammatory Bowel 
Diseases and patient response to therapy 14.  For example, inhibition of NF-kB 
signaling, in epithelial cells, was found to result in impaired antimicrobial defense, 
enhanced bacterial penetration and a heightened inflammatory response15.  The 
NF-κB family of transcription factors consists of five members: RelA (p65), c-Rel, 
RelB, p50/p105 and p52/p10016. Dimers of these proteins are kept inactive by 
interacting with inhibitory proteins of the IκB family. The IκB kinase (IKK) complex 
can target the IκB proteins for proteosome-mediated degradation. The canonical 
NF-κB signaling pathway requires the regulatory protein IKKγ/NEMO and the 
catalytic subunit IKK2 (IKKβ) and leads to RelA nuclear translocation. 
Proinflammatory cytokines such as TNF-α and bacterial antigen can trigger this 
process.  
          The alternative pathway involves IKK1 and promotes nuclear accumulation 
of p52/RelB dimers. This pathway is important for lymphoid organogenesis and 
lymphocyte development. Mice lacking the regulatory protein NEMO, within the 
epithelial cells, develop spontaneous colitis at an early age17. Some of the early 
events are innate immune system activation and increased epithelial cell 
apoptosis. Interestingly intestinal epithelial deletion of IKK2, another component 
of the canonical pathway does not lead to this phenotype since the alternative 
pathway subunit IKK1 has a compensatory role. The proinflammatory, NF-kB 
dependent effects in macrophages and T cells during later stages of colitis, may 
overshadow the initial protective role of epithelial NF-kB. In line with these 
observations, loss of IKKβ in macrophages and neutrophils was able to attenuate 
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chronic colitis in IL10 KO mice18.  
          Inflammatory Bowel Diseases (Crohn's Disease and Ulcerative Colitis) 
have a relapsing/remitting pattern. Nevertheless, some patients enjoy prolonged 
periods of remission while others have rather continuous activity and poor 
response to anti-inflammatory treatment. In light of the opposing role of NF-kB in 
acute vs. chronic colitis and epithelial vs. immune cells , it will be important to 
determine whether cell specific impairment in this signaling pathway correlates 
with clinical course and response to therapy.  
          An important target of NF-kB/RelA in intestinal epithelial cells is the 
polymeric immunoglobulin receptor (pIgR)19. This receptor is responsible for the 
active transport of IgA into the gut lumen. The pIgR is synthesized in the 
endoplasmic reticulum and delivered to the basolateral membrane of the 
intestinal epithelial cell via the Golgi apparatus. At this level, pIgR binds an IgA 
dimer and the receptor/ligand complex reaches the apical membrane through the 
endosomal compartment. Cleavage of the pIgR extracellular domain releases the 
SC (secretory component) with or without IgA dimer. The SC fragment prevents 
pIgA (polymeric IgA) degradation and thus enhances humoral immunity. 
Moreover, the SC fragment can bind bacterial components such a C. Difficile 
toxin A and fimbriae of enterotoxigenic E. coli, and thus limit their pathogenicity20-
21.  
           In addition to a direct effect on epithelial cells, bacteria can induce pro-
inflammatory cytokines and chemokines with subsequent immune cell influx and 
increased tissue damage. Free SC can bind IL-8 and scavenge this 
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proinflammatory chemokine thus limiting neutrophil infiltration22.  Mice lacking 
pIgR expression are more susceptible to DSS (dextran sodium sulphate) induced 
colitis23. Interestingly these mice have increased IgA production possibly 
reflecting a role of pIgR on B cells, or more likely a response to increase bacterial 
antigen exposure due to a barrier defect.  
          The incidence and relevance of pIgR abnormalities in patients with 
Inflammatory Bowel Disease has not been established. Moreover, pIgR 
polymorphisms have not been associated with increased risk of Crohn's Disease 
or Ulcerative Colitis. It is conceivable that variations of pIgR expression reflect 
the activity of epithelial NF-kB. Recent in-vitro studies, using the HT-29 human 
colon carcinoma line, highlighted the importance of the canonical NF-kB/RelA 
component. Upon stimulation with TNFα, these cells respond by quickly 
upregulating IL-8 secretion. In contrast, pIgR expression peaked at 24 hrs at the 
time when the proinflammatory chemokine IL-8 was downregulated. Given prior 
evidence that the SC fragment can bind and neutralize IL-8, we may consider the 
late pIgR expression as a defense mechanism needed to terminate the acute 
inflammatory response.  
          The other important observation is that chronic exposure of intestinal 
epithelial cells to TNFα maintains high pIgR expression24. Mucosal TNFα is 
elevated in patients with Inflammatory Bowel Diseases and thus the abnormal 
expression of pIgR could reduce the defense mechanisms of the epithelial 
barrier. Furthermore, although TNFα blockade is highly successful in early versus 
late disease, the net effect of pIgR expression may lead to epithelial cell immune 
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dysfunction and partly explain the less optimal long-term success. It also implies 
that knowledge of pIgR expression in mucosal biopsies may help select the best 
candidates for anti-TNF therapy in patients with Inflammatory Bowel Diseases.  
           As outlined above, one of the main functions of polymeric immunoglobulin 
receptor is IgA transport across the epithelial cells. IgA plays an important role in 
mucosal immunity. IgA has two subclasses, IgA1 and IgA2. IgA2 predominates in 
the mucous secretions whereas IgA1 is more abundant in the serum. The dimeric 
form of IgA but not the monomer interacts with the pIgR at the basolateral 
surface of the epithelial cells. This complex is released at the apical site together 
with the secretory component (SC) which retards its digestion in the gut lumen. It 
is important to realize that compared to IgG antibodies, IgA does not trigger 
complement activation. Given the enormous amount of IgA produced in response 
to commensal flora this property prevents an inappropriate innate immune 
response to commensals, as seen in patients with Inflammatory Bowel 
Diseases25.   
          Evaluation of patients with inflammatory bowel diseases has demonstrated 
an increase in IgG1 antibody subclass26, which is a rather potent activator of the 
complement system. Aside from the subsequent induction of pro-inflammatory 
cytokines and chemokines, this also reflects a break in tolerance to gut bacteria.  
B cell numbers are increased in Inflammatory Bowel Diseases. This may 
theoretically compensate for the IgG shift. Nevertheless, J chain expression in 
the lamina propria B cells is decreased27 which means less IgA dimers are 
formed. Since only polymeric IgA can be transported by pIgR this may translate 
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in a luminal IgA deficiency.  
          Induction of NF-kB downstream of TNFα and toll receptor signals can also 
trigger regulatory molecules. The zinc finger protein A20 is part of this negative 
feedback regulatory loop. A genome wide association study has identified A20 as 
a susceptibility gene for Crohn's Disease. In support of its role in inflammation 
control, A20 KO mice develop severe multi-organ inflammation. Specific 
deletions of A20 in enterocytes do not result in spontaneous colitis. Nevertheless, 
these mice are more susceptible to DSS induced colitis28.  Although NF-kB 
expression protects enterocytes from apoptotic signals, overactivation in the 
absence of A20 may have the opposite effect. The TLR-MyD88-NF-kB signaling 
axis may also confer protection form apoptosis. Activation of A20 secondary to 
the pro-inflammatory cytokine TNFα may act cooperatively but independent of 
the former pathway since the A20/MyD88 double KO mice are more susceptible 
to colitis then either single KO strain28. Since enterocyte, specific A20 KO mice 
do not develop spontaneous colitis, it is possible that A20 plays a more important 
role under pathologic conditions characterized by unchecked proinflammatory 
cytokine secretion such as TNFα. On the other hand, transfer of A20 KO bone 
marrow into irradiated wild type mice leads to spontaneous colitis that can be 
prevented by antibiotic treatment. This suggests that myeloid but not enterocyte 
A20 expression prevents inflammatory response against gut flora under normal 
conditions.  
          In chapter 2, I propose that the coordinated expression of NF-kB/RelA, 
pIgR, IgA, A20, TNF and IL-8 defines unique phenotypes in patients with 
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Inflammatory Bowel Diseases. Figure 1.2 depicts my proposed model whereby 
bacterial and pro-inflammatory signals converge on the NF-kB transcriptional hub 
to induce epithelial defense mechanisms: anti-apoptotic (RelA), bacterial immune 
exclusion (pIgR, IgA), anti-inflammatory (A20), pathogen elimination (TNFα, IL-
8). Deregulation of these mechanisms in IBD patients can generate a state of 
mucosal innate immune deficiency with secondary activation of the acquired 
immune arm. Homeostatic functions of the gut epithelial barrier such as IgA, 
mucus and antimicrobial peptide secretion require a high level of synthetic 
capacity and metabolic activity.  
          Dysfunction of the protein folding process or insufficient generation of ATP 
is likely to promote ER (endoplasmic reticulum) and mitochondrial stress 
responses followed by apoptosis and inflammatory mediators. Under these 
conditions, restitution of homeostasis requires adequate protein and organelle 
turnover. Autophagy is an evolutionary conserved pathway triggered by 
ER stress and starvation. In the process of autophagy, cytoplasmic material 
(protein, organelles) is engulfed in membrane-coated autophagosomes, which 
subsequently fuse with endosomes and lysosomes in order to form 
autolysosomes that degrade the ingested material.  
          The autophagy process is also utilized to remove intracellular bacteria. A 
genome wide analysis linked Crohn's Disease to the autophagy gene ATG16L1 
(ATG16L1T300A)29. Importantly this gene was associated with impaired clearance 
of Salmonella typhimurium. Moreover, studies in mice hypomorphic for ATG16L1 
protein expression, as well as ileal biopsies form IBD patients revealed defective 
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Paneth cell function30. These cells are found at the bottom of the intestinal crypts 
and regulate the bacterial microenvironment by secreting antimicrobial peptides. 
          Morphological analysis of these Paneth cells also revealed degenerating 
mitochondria. Surprisingly these cells expressed higher levels of PPARΎ 
(peroxisome proliferator-activated receptor), a master regulator of adipocyte 
differentiation as well as adiponectin an adipose tissue anti-inflammatory 
adipokine. Intestinal microbiota in obese patients is characterized by an 
increased ratio of Firmicutes relative to the Bacteroides species31-32. Interestingly 
the abundance of the Bacteroides species in the murine gut is positively 
correlated with the expression of α-defensins33. Furthermore, metabolic disorders 
associated with low-grade systemic inflammation (type II diabetes, obesity) are 
associated with increased gut permeability. Thus, both inflammatory bowel 
disease and metabolic disorders appear to share Paneth cell deregulated 
function and dysbiosis. Upregulation of adipose tissue signature factors, PPARΎ 
and adiponectin may represent a defense mechanism since both exert protective 
effects in gut inflammatory states34-35.  Therefore, adipose tissue specific factors 
can regulate innate immune response in the gut mucosa. 
           The epidemic of obesity has affected several autoimmune conditions. In 
spite of the malabsorbtive nature of Inflammatory Bowel Diseases the percent of 
overweight/obese patients is rising36. Moreover, increased incidence of metabolic 
syndrome can create a background of low-grade systemic inflammation. A 
signature feature of Crohn’s Disease is the development of mesenteric fat 
inflammation37. Macroscopically, the fat tissue wraps around the diseased bowel 
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segment, and give rise to what is called  “creeping fat”. Given the transmural 
nature of the inflammation in Inflammatory Bowel Disease, the adipose tissue 
inflammation has generally been dismissed as a secondary event. Moreover, 
until recently, adipose tissue was primarily viewed as an energy depot.   
           Emerging data from multiple medical fields clearly demonstrate that 
adipocytes and resident adipose tissue macrophages function as bacterial 
sensors and thus promote chronic inflammation38. More importantly, adipose 
tissue is a source of pro-inflammatory cytokines such as angiotensin, TNF-α, IL-
6- as well as the anti-inflammatory adipokine, adiponectin and IL-10. The 
“creeping fat” that surrounds the bowel can thus become a source of 
inflammatory mediators at the expense of the anti-inflammatory adiponectin and 
contribute to chronic bowel inflammation. Both macrophages and adipocytes 
share regulatory pathways relevant to metabolism and innate immunity 39-40. 
Signaling through adiponectin receptors regulates overlapping pathways 
responsible for energy balance, insulin sensitivity and macrophage polarization. If 
we acknowledge the plasticity of adipose cells that acquire a macrophage like 
phenotype during inflammation, the LPS buffering capacity of adiponectin and 
the availability of endogenous TLR4 ligands in the fat depot, then metabolism 
and inflammation can no longer be considered as separate processes.  
          Previous studies addressing the role of adiponectin in experimental colitis 
yielded controversial results 41-42. In chapter 3 I address  the effects of 
adiponectin overexpression in a model of DSS and the therapeutic benefit of a 
plant homologue43.  Adiponectin (AdipoQ) is unique among adipokines, because 
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its circulating levels are inversely related to the adipose mass44-45. The human 
adiponectin gene contains a signal sequence, a collagen like domain, and a 
globular domain similar to the complement factor C1q. Biological effects of 
adiponectin depend upon the formation of multimeric complexes. The basic unit 
is a trimer, which can associate through disulfide bonds to generate hexamers 
and dodecamers referred to as low, medium and high molecular weight 
adiponectin (LMW, MMW, HMW) respectively46.  
          Cleavage of the adiponectin molecule by leukocyte esterase can release 
the globular part, which retains biological activity. It is important to distinguish 
between these isoforms since they may have opposing effects on inflammation. 
Both pro- and anti-inflammatory effects have been described for all forms of 
adiponectin47-50. This is in part explained by the experimental conditions and cell 
type, although LPS contamination is another important factor51. Recent studies 
suggest that HMW weight adiponectin is the main anti-inflammatory moiety52. In 
vitro experiments have shown that globular adiponectin induces NF-kB and pro-
inflammatory cytokines, but prolonged exposure blocks further activation. In 
contrast, HMW adiponectin can quickly prevent NF-kB activation53.  
          Studies in Crohn’s disease patients and experimental colitis have reported 
total adiponectin level rather than HMW.  Adiponectin production is regulated at 
transcriptional and post-translational levels. During adipogenesis, several 
transcription factors, including PPARγ, bind its promoter to upregulate mRNA 
expression54. Following translation, adiponectin undergoes hydroxylation of 
proline and lysine residues as well as glycosylation of hydroxylysines. These 
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processes along with formation of disulfide bonds are required for HMW complex 
assembly55-56. Furthermore, these bonds are essential for adiponectin secretion.  
            An endoplasmic reticulum (ER) chaperone protein, ERp44, retains 
adiponectin within the cell. Ero1-Lα, another chaperone, competes with 
adiponectin for binding to ERp4457. Ultimately, the balance between the two ER 
proteins may regulate the amount of secreted adiponectin. The volume of 
adipose tissue influences plasma levels of adiponectin. Obese patients have 
lower adiponectin levels. Weight loss through caloric restriction, exercise or 
bariatric surgery increases adiponectin or at least the ratio of HMW to total 
adiponectin58-61. Similar to findings in Crohn's Disease, obesity is associated with 
adipocyte ER stress, which leads to decreased adiponectin exocytosis and 
hypoadiponectemia62.  In-vivo and in-vitro studies suggest that the visceral rather 
than the subcutaneous fat is the main source of adiponectin. Importantly, the size 
of adipocytes correlates with the amount of secreted protein. Large, insulin 
insensitive adipocytes have lower secretion61,63.   
           Two main adiponectin receptors with homology to G protein-coupled 
receptors have been identified. These receptors have distinct tissue specificities 
within the body and have different affinities to the various forms of adiponectin  
(mono or multimers)64.  Adiponectin binds to the extracellular COOH terminus of 
adiponectin receptors (AdipoR1 / AdipoR2) and recruits the adapter APPL1 
(adaptor protein containing PH domain) which in turn activates AMPK (AMP-
activated protein kinase)65. APPL1 is rather promiscuous and interacts with at 
least 14 proteins that modulate apoptosis66, endosomal localization of proteins67, 
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and chromatin remodeling. Recruitment of APPL1 by adiponectin receptors 
induces AMPK (5'-AMP activated protein kinase) phosphorylation. This process 
requires the upstream LKB1 kinase and to a lesser extent Ca2+/ calmodulin 
dependent protein kinase kinase (CaMKK)68.  Activation of AMPK by CaMKK can 
provide a direct link between ER stress and autophagy.  Decreased cellular ATP 
during starvation or states of mitochondrial dysfunction can also activate AMPK. 
Under these circumstances, the upregulation of adiponectin in Paneth cells 
carrying the  ATG16L1T300A mutation may be interpreted as a trigger for 
autophagy.  
           APPL1 and AMPK also modulate PI3K/AKT (phosphoinositide-3-kinase 
and protein kinase B) and mTOR (mammalian target of rapamycin), which 
function as regulatory hubs in both metabolic and immune processes. Signaling 
cascades that polarize T cell and macrophage responses incorporate these 
molecules69. Therefore, adiponectin can regulate both the acquired and innate 
arms of the immune responses. AICAR (5 aminoimidazole-4-carboxamide 
ribose) a non-specific AMPK activator ameliorates experimental autoimmune 
encephalitis70-71, a model dependent on Th1/Th17 effector cells.  
           Analysis of both murine and human macrophage cell lines found high 
basal expression AMPK, predominantly the α1 isoform72. The cytokine milieu can 
regulate its expression in these cells. Anti-inflammatory cytokines IL-10 and 
TGFβ upregulate while TLR4 agonist, LPS downregulate its expression. 
Inhibition of macrophage AMPK amplifies the TNFα and IL-6 response to LPS. 
Mechanistically the AMPK enhances Akt activity, which in turn phosphorylates 
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and inactivates its substrate GSK3-β. This Akt target promotes Th1 cytokine 
expression. In addition, GSK3-β can negatively regulate CREB (cyclic AMP 
responsive element binding protein) expression, a known activator of IL10 
production in macrophages. Moreover, AMPK prevents IkB degradation and 
indirectly the NF-kB translocation to the nucleus. Overall, the activity of AMPK in 
macrophages appears to promote an M2 (alternatively activated) anti-
inflammatory phenotype.  
          Previous unpublished data from my laboratory indicate decreased mucosal 
adiponectin receptor (AdipoR1/R2) expression in subsets of patients with 
moderate to severe Crohn’s disease. It is currently unknown whether this is a 
global event, or is restricted to certain cell types. Peroxisome proliferator-
activated receptor gamma(PPARγ) can increase adiponectin sensitivity by 
upregulating its receptors73, while the opposite may be true for the pro-
inflammatory adipokine, angiotensin. Thus, PPARγ can enhance macrophage 
response to adiponectin.                      
          Intestinal epithelial cells produce angiotensin converting enzyme (ACE) 
that mediates the conversion of angiotensinogen (produced by adipocytes and 
macrophages) into the biologically active angiotensin I (ANG-I)74. Angiotensin 
has pro-inflammatory and profibrotic activity and can negatively regulate 
adiponectin and adiponectin receptors. A significant number of Crohn's Disease 
patients develop fibrotic strictures and require surgical intervention. Adiponectin 
can prevent fibrosis by reducing the TGFβ signaling75 in an AMPK and PPARα 
dependent manner. Angiotensin can downregulate AMPK /PPARα and enhance 
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TGFβ expression76. Therefore, the relative balance of adiponectin and 
angiotensin could modulate TGFβ dependent epithelial-to-mesenchimal transition 
and determine the Inflammatory Bowel Disease behavior.  
          Despite normal/reduced ACE activity in the serum, ACE levels are 
increased in the mucosa of Crohn’s patients and correlate with disease activity77. 
Since macrophages and adipocytes produce angiotensinogen (AGT)78-80, 
epithelial ACE may promote inflammation within the gut and mesenteric fat. 
Medications that block angiotensin increase adiponectin, adiponectin receptor 
expression, and ameliorate experimental colitis, thus supporting these 
observations81. The relative antagonism of adiponectin and angiotensin as well 
as competition for PI3/AKT and p38MAPK pathways could theoretically alter 
epithelial cell cycle, and sensing of bacteria82. This in turn would influence NF-kB 
dependent targets such as pIgR (polymeric IgA receptor), tight junction proteins, 
and inflammatory cytokines. 
           Adiponectin induces mucosal IL-10 production (unpublished data) and 
activates p38MAPK (p38 mitogen-activated protein kinase). The p38MAPK/IL-
10/STAT3 axis inhibits inflammation-induced ER stress response mechanism83. 
STAT3 expression positively correlates with AdipoR2 expression in Crohn’s 
Disease patients, and adiponectin reduces ER stress response in DSS colitis. 
Thus, adiponectin may activate p38MAPK/IL-10/STAT3 axis during states of 
inflammation. AMPK activation downstream of adiponectin receptor could 
dampen the Th1/Th17 immune response during acute and chronic phases of 
colitis while promoting the M2 type macrophages (Figure 1.3) 
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          Environmental factors can affect adipose tissue volume and distribution. 
Prior studies in our laboratory identified a link between Aryl hydrocarbon pathway 
(AhR), abnormal adipocyte metabolism and inflammation84.  Specifically, AhR 
agonist PCB77 promoted adipose tissue Th1 cytokine expression, activation of 
the renin angiotensin system and decrease adiponectin. Cigarette smoke 
contains a mixture of AhR agonists and is associated with complicated forms of 
Crohn's Disease. It is well known that the gene/environment interplay contributes 
to the pathogenesis of chronic disease states such as IBD.                  
           Perhaps one of the best examples of this type of gene/environment 
interplay is that of the pregnane X receptor (PXR) signaling pathway.  The 
association between IBD and the PXR pathway was first identified following gene 
expression profiling of inflamed tissues obtained from patients with Ulcerative 
Colitis and Crohn Disease.  Increasing evidence supports the idea that activation 
of the AhR by environmental factors may similarly impact the severity of IBD.  
Like the PXR, the AhR regulates both xenobiotic metabolism and the 
inflammatory response.  For example, exposure to environmental agents such as 
PCB 77 and cigarette smoke activates the AhR leading to the upregulation of 
phase I (CYP1A1 and CYP1B1), and phase II (UGT1A1 and GSTA1) of the 
xenobiotic metabolism.      
          The AhR is a basic helix-loop helix transcription factor that in its latent 
form, resides in the cytosol as a complex comprised of a dimer of heat shock 
protein of 90 kDa (HSP90), an immunophilin (ARA9) and p2385.  The presence of 
an AhR agonist triggers translocation of the AhR into the nucleus where it 
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dimerizes with its DNA binding partner, aryl hydrocarbon nuclear translocator 
(ARNT) and binds specific DNA recognition sites, the xenobiotic response 
elements (XRE) and thus either upregulates or downregulates a battery of genes.  
Prototypical AhR target genes most commonly studied are those involved in 
xenobiotic metabolism, in particular, CYP1A1 and CYP1B. These genes encode 
enzymes that are highly induced following exposure to AHR agonists86.  AhR 
translocation to the nucleus can also trigger an auto-regulatory negative 
feedback thorough aryl hydrocarbon receptor repressor (AHRR).  
          Proinflammatory metabolites of arahidonic acid (i.e. lipoxin A4) and 
tryptophan were recently identified as relatively potent AhR agonists87-89.  This 
indicates that the AhR signaling pathway plays a role in the regulation of the 
inflammatory responses. For example, 6-formylindolo [3, 2-b] carbazole (FICZ) a 
tryptophan derivative, generated by UV light exposure, is a potent AhR inducer 
and can be detected in human urine. Interestingly, several gram positive and 
negative bacteria present in the human gut can also process tryptophan, and 
thus generate AhR ligands in the form of indoles. On the other hand, indole-
negative bacteria produce oxygenases that interfere with indole signaling. Taken 
together these observations suggest that the relative distribution of indole 
positive/negative bacteria can modulate intestinal epithelial and immune cells 
function.  
          Dietary habits can influence the amount of tryptophan intake and alter the 
composition of bacterial biofilm.  AhR agonists that are typically used in research 
to induce the AhR signaling pathway are environmental contaminants, such as 
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dioxin (TCDD or 2, 3, 7, 8-Tetrachlorodibenzo-p-Dioxin) and other 
polychlorinated hydrocarbons such as PCBs.  In addition, studies have shown 
that polyaromatic hydrocarbons present in cigarette smoke act as potent AhR 
agonists.  In fact, the AhR has been recently identified as a major regulator of 
responses elicited by exposure to cigarette smoke. The aryl hydrocarbon 
receptor is strongly expressed in the gut, particularly in small bowel intestinal 
epithelial cells.  Furthermore, either oral or intraperitoneal administration of AhR 
agonists resulted in rapid induction of CYP1A1 expression in the intestinal crypts.  
Thus, a number of ubiquitous xenobiotics, such as PCBs and cigarette smoke, 
are capable of activating the AhR signaling pathways in cells of the 
gastrointestinal mucosa.                          
         The canonical AhR pathway activates nuclear enzymes important for endo-
and xenobiotic metabolism (CYP450). AhR can also interact with NF-kB subunits 
(non-canonical pathway) and modulate inflammation90.  Several mechanisms 
have been proposed regarding the AhR /NF-kB interaction91: 1) direct binding 
NF-kB to CYP ( cytochrome) genes; 2) transcriptional repression involving 
factors such as  PPAR, RXR and LXR; 3) post-transcriptional regulation of CYP 
activity through heme-oxygenase . 
        The differentiation of naïve CD4 T cells into Th1 is important for controlling 
intracellular bacterial infections while Th2 cells initiate antibody responses 
against extracellular pathogens.  Aryl hydrocarbon receptor plays an important 
role in the development of both Th memory and Th effector cells (Figure 1.4) and 
by extension in the development of chronic inflammatory conditions like IBD92-94.  
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The CD4+ Th17 cells are defined by a high AhR expression and a combination of 
IL17A, IL17F and IL22 cytokines95. Activation of Th17 cells by FICZ (short acting 
AhR agonist) augment these cytokines production and induce the expression of 
AhR battery genes.  Supporting the relationship between AhR and Th17 cells is 
the fact that Th17 cells from AhR KO mice cannot produce IL22, implying that 
AhR activation is required for IL-22 production in this T cell subset. In addition, 
since macrophages and dendritic cells induce IL22 through IL-23 release 
indicates that IL23 functions downstream of the aryl hydrocarbon receptor (AhR).  
          Recent studies have also demonstrated that AhR can bind the IL17 
promoter and this interaction is negatively regulated by the nuclear receptor liver 
X receptor (LXR) 96. Th17 development is impaired in AhR KO mice. On the other 
hand, Th17 polarizing cytokines, TGFβ and IL6 induce AhR expression in these 
cells97. Increased AhR expression was correlated with lower signal transducer 
and activator of transcription 1 (STAT1) levels. This may suggest that AhR can 
antagonize the negative effect of IFNΎ (STAT1 activator) on Th17 cells 
development97.   
          Intestinal epithelial cells (IEC) can also express IL22 that promotes release 
of antimicrobial peptides. There is no evidence that AhR ligands are driving IEC 
IL22 secretion but given the role of NF-kB in Paneth cells and NF-kB – AhR 
interaction, the latter may modulate the innate immune function of the 
gastrointestinal mucosa. In favor of this interaction is the fact that IL22 
expression is upregulated in the gut mucosa of Crohn's Disease patients and 
plays an important role in experimental colitis as well.    
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          Short acting AhR ligands, such as FICZ promote inflammation. In contrast, 
the long acting agonist TCDD has been associated with immunosupression. 
Several mechanisms may be involved in this process: 1) direct effect on T cells; 
2) modulation of antigen presenting cell (APC) function; 3) toxic effect on bone 
marrow stem cells. In a mouse model of IBD (TNBS induced colitis), TCDD 
induced forkhead box P3 (FoxP3) expression and decreased the severity of 
colitis98. A similar mechanism has been proposed in a model of experimental 
autoimmune encephalitis (EAE) 95. Dendritic cells (DC) can polarize naïve T cells 
toward the Treg phenotype by expressing IL10 and decreasing the availability of 
tryptophan. AhR is required to induce indoleamine 2, 3-dioxygenase (IDO) 
expression in DC. This enzyme catabolizes tryptophan into metabolites like 
kynurenine (Kyn) which promotes inducible Treg (iTreg) development.  Taken 
together, the AhR pathway can regulate the Th17/Treg balance.  
          Although animal studies using TCDD indicate that AhR ameliorates 
inflammation this may not apply to human conditions such as IBD (excluding 
accidental exposure). The naturally occurring ligands are rapidly metabolized, 
whereas synthetic, long acting compounds such as TCDD persist and will 
accumulate in the body. Therefore, experiments in AhR KO and heterozygote 
mice will allow us to determine the overall effects of endogenous ligands on the 
development of Inflammatory Bowel Diseases. 
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Figure 1.1 Inflammatory Bowel Diseases paradigm 
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Figure 1.2 Epithelial Innate Immune Molecular Targets 
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Figure 1.3 Role of Adiponectin in Inflammatory Bowel Disease 
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Figure 1.4 Aryl hydrocarbon receptor and T cell polarization 
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Chapter Two  
The content of Chapter 2 has been published in the Journal of Mucosal 
Immunology. Permission to reproduce this material has been obtained from the 
Nature Publishing Group. 
   
SIGNATURE BIOMARKERS IN CROHN ’S DISEASE: TOWARD A 
MOLECULAR CLASSIFICATION 
 
Synopsis 
In an effort to develop a molecular classification scheme for Crohn ’ s 
disease (CD), mucosal biopsies from 69 CD patients and 28 normal controls 
were analyzed for expression of the RelA subunit of nuclear factor (NF)- kB, A20 
(a negative regulator of NF- kB), polymeric immunoglobulin receptor (pIgR), 
tumor necrosis factor (TNF), and interleukin (IL)-8. Principal component analysis 
was used to classify individuals into three subsets based on patterns of 
biomarker expression. Set 1 included normal subjects and CD patients with mild 
disease and good responses to therapy, thus defining “normal” biomarker 
expression. CD patients in set 2, characterized by low expression of all five 
biomarkers, had moderate to severe disease and poor responses to 
immunosuppressive and anti-TNF therapy. Patients in set 3, characterized by low 
expression of RelA, A20, and pIgR, normal TNF and elevated IL-8, had acute 
inflammation that responded well to therapy. Classification of CD patients by 
these biomarkers may predict disease behavior and responses to therapy. 
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Introduction 
Crohn’s disease (CD) is a chronic disorder characterized by patchy 
transmural inflammation of the small and / or large bowel, thought to result from 
an inappropriate inflammatory response to normal components of the intestinal 
microbiota in genetically predisposed individuals. 1 – 3 Progress has been made in 
characterizing the effector cells and molecules that comprise the inflammatory 
response, and current biological therapies are targeted toward neutralizing these 
effectors. 4 – 7 However, recent evidence suggests that the primary defect in CD 
may actually be a defective innate immune response within the intestinal 
mucosa. 8,9 There is general agreement that molecular biomarkers for CD are 
needed to improve diagnosis and guide therapies.10  The aim of this study was to 
identify a set of biomarkers representative of the innate immune response in the 
gut mucosa, which could be used to classify CD patients into molecular phe-
notypic subsets predictive of disease behavior and responses to therapy.  
The association of nuclear factor (NF- kB) signaling with induction of pro-
inflammatory cytokines has led to the hypothesis that excessive activation of NF-
kB is central to the pathogenesis of CD.11,12  Recent findings, however, have 
suggested that activation of NF-kB may be crucial for regulation of intestinal 
inflammation and maintenance of epithelial barrier function. 13–15 Thus 
“physiological” inflammation induced by RelA signaling may be important for 
maintaining epithelial homeostasis in the gut, and reduced expression of RelA 
could contribute to the “innate immunodeficiency” seen in CD.  
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 NF-kB induces expression of A20, an ubiquitin-modifying enzyme that 
negatively regulates the NF-kB activation pathway. 16,17  Mice genetically deficient 
in A20 are hypersensitive to tumor necrosis factor (TNF)- and Toll-like receptor 
(TLR) induced NF- kB activation, and develop severe intestinal inflammation. 18 
We hypothesized that reduced expression of A20 in the intestinal mucosa could 
therefore be a risk factor for CD.  
Secretory antibodies of the IgA class (SIgA) form the first line of antigen-
specific immune protection at mucosal surfaces and promote homeostasis 
between the intestinal epithelium and the commensal microbiota. 19, 20   Transport 
of IgA across intestinal epithelial cells into the gut lumen is mediated by the 
polymeric immunoglobulin receptor (pIgR). 21, 22   Following transport, the 
extracellular domain of pIgR is cleaved to form secretory component (SC), which 
remains associated with SIgA and confers additional innate immune functions. 23 
,24  Targeted deletion of the Pigr gene in mice causes elevated serum IgA, 
increased mucosal permeability, and increased susceptibility to experimental 
colitis. 25 – 27 Expression of pIgR in intestinal epithelial cell is upregulated by TNF and 
TLR signaling via activation of NF- kB. 21, 22   We hypothesized that diminished 
expression of pIgR in the intestinal mucosa could lead to increased inflammatory 
responses to the commensal microbiota.  
The pro-inflammatory cytokine TNF is associated with mucosal 
inflammation in CD, and therapies designed to neutralize TNF activity have 
shown promise in a subset of CD patients who are refractory to conventional 
therapies. 6, 28 TNF also has protective roles in innate immunity, including 
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induction of NOD2 and pIgR expression, epithelial restitution, and control of 
potentially pathogenic luminal bacteria. 29 – 32  We hypothesized that although 
optimal expression of TNF in the intestinal mucosa may promote physiological 
inflammation, reduced TNF could lead to defective innate immunity.  
Interleukin (IL)-8 is a potent chemoattractant for neutrophils, the major 
component of the cellular infiltrate in acute inflammation. 33 Although neutrophils 
contribute to mucosal inflammation through the release of soluble mediators, 
they also play an important role in removal of bacteria and foreign debris that 
could otherwise promote a granulomatous response by mucosal macrophages. 8, 
9 Accordingly, we investigated IL-8 as a potential biomarker for acute 
inflammation in CD patients.  
Given the heterogeneous clinical presentation in CD, we anticipated that 
no single biomarker would accurately predict disease behavior. We utilized a 
multifactorial approach to develop a molecular classification scheme, based on 
expression levels of RelA, A20, pIgR, TNF, and IL-8 in the intestinal mucosa of 
CD patients and normal controls.   
 
Materials and Methods 
Study subjects.  Peripheral blood and mucosal biopsies were obtained from 
individuals undergoing colonoscopy at the University of Kentucky Medical 
Center, after institutional review board approval and written informed consent. 
For CD patients, the indication for colonoscopy was either to evaluate disease 
exacerbation or to screen for dysplasia and colorectal cancer. Diagnosis of CD 
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was based on clinical, radiological, and endoscopic criteria according to the 
Montreal classification, 41 supported by histopathological findings. Active disease 
was defined by a Harvey–Bradshaw index 40 >4 or endoscopic evidence of active 
inflammation. Control subjects aged 50 years or older underwent screening 
colonoscopies for colon cancer in accordance with current guidelines. Control 
subjects under 50 years of age underwent colonoscopy for evaluation of 
constipation or chronic abdominal pain. Individuals were classified as “normal” 
when endoscopic, radiologic, and pathologic evaluation of randomly obtained 
biopsies revealed no disease of the small or large bowel.  
 
Analysis of mRNA levels in colonic and ileal mucosa.  Biopsied tissue was 
immediately immersed in an RNA-stabilizing solution (RNAlater; Qiagen, 
Valencia, CA) and stored at − 80 °C. Total RNAwas purified using the Qiagen 
RNeasy Protect mini kit (Qiagen) according to the manufacturer’s directions. 
RNA was reverse-transcribed to generate cDNA templates using the TaqMan 
Gold RT-PCR kit (Applied Biosystems, Foster City, CA). Specific mRNA levels 
were quantified by real-time reverse transcription PCR, using the ABI Prism 7700 
Sequence Detection System (Applied Biosystems) as previously reported. 32 The 
level of 2-microglobulin mRNA, which did not vary between normal subjects and 
CD patients, was used to normalize mRNA levels for test genes according to the 
following formula: (2 -(C test − C 2-microglobulin)) × 100 %.  
Preliminary studies indicated that gene expression did not vary significantly in 
different regions of the large bowel (cecum, transverse colon, and rectum) within 
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each individual. Accordingly, biopsies of non-inflamed mucosa from different 
regions of the colon were pooled into a single sample for mRNA analyses. 
 
Measurement of serum IgA and immunolocalization of IgA and pIgR.  Serum IgA 
levels were measured using a commercial ELISA kit for human IgA (Bethyl 
Laboratories, Montgomery, TX). Mucosal biopsies were immediately fixed in 
formalin and then embedded in paraffin. The sections (5 – 7 μm) were mounted 
on glass slides, deparaffinized, rehydrated, quenched with 3 % H2O2, and treated 
for 10minwith a citricacidbased antigen-unmasking solution (Vector Laboratories, 
Burlingame, CA). Sections were blocked with normal goat serum (1 % in 
phosphate-buffered saline) and incubated overnight at 4°C with primary 
antibodies: monoclonal mouse anti-human IgA, (Santa Cruz Biotechnology, 
Santa Cruz, CA; catalog no. sc66185) (diluted 1:50) and polyclonal rabbit anti-
human SC (the extracellular domain of pIgR) 45 (diluted 1:200). Sections were 
washed and incubated for 1 h with a mixture of Cy2-conjugated goat anti-mouse 
IgG and Cy3-conjugated goat anti-rabbit IgG (Jackson ImmunoResearch 
Laboratories, West Grove, PA; catalog nos. 115225-146 and 111-165-144). 
Sections were counterstained with 4', 6-diamidino-2-phenylindole dihydrochloride 
(Molecular Probes Invitrogen, Eugene, OR) to visualize nuclei and mounted with 
VECTASHIELD medium (Vector Laboratories). Stained sections were imaged 
with an Olympus BX51 microscope, using a ×20 objective. ImagePro software 
was used to generate the composite images.  
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Analysis of NOD2 mutations.  Genomic DNA was extracted from whole blood 
using the AquaPure Genomic DNA Isolation kit (BioRad, Hercules, CA). The 
R702W, G908R, and 1007fsinsC polymorphisms in the NOD2 gene were 
detected by restriction fragment length polymorphism analysis of PCR-amplified 
DNA, as described. 42  
 
Statistical analyses.  All statistical analyses were performed using StatView 
software (SAS Institute, Cary, NC). Because biomarker expression did not follow 
normal Poisson distributions, non-parametric statistical analyses were used for 
all comparisons. Mann – Whitney analysis was used to test for significant 
differences among groups of individuals. Paired sign analysis was used to 
compare differences in gene expression in paired biopsies within individuals. 
Spearman correlation analysis was used to test for correlations in mRNA levels 
among different biomarkers. PCA 36 was used to reduce the five variables 
(biomarkers) into two PCs. Expression levels for biomarkers from non-inflamed 
colon or ileum mucosa from all subjects in the cohort (normal controls and CD 
patients) were included in the PCA. The goodness-of-fit of the two PCs for the 
colon and ileum data sets was tested by χ² analysis. To assign individual scores 
for PC1 and PC2, the expression level for each of the five biomarkers for each 
individual was first normalized to the mean for that biomarker for all subjects in 
the cohort. Individual scores for PC1 and PC2 were then calculated as the sum 
of the normalized value for each biomarker times the weight for that biomarker. 
Individuals were classified into subsets according to their scores for PC1 and 
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PC2. The χ² analysis was used to test the effects of clinical parameters and 
medications at time of biopsy on distribution of CD patients into phenotypic 
subsets. 
 
Results 
Biomarker expression in CD patients and normal controls  
Mucosal biopsies from the colon and /or terminal ileum were obtained at 
colonoscopy from 69 CD patients and 28 normal controls (Figure 2.1 a). Based 
on visual inspection and histology, tissues were classified as inflamed or non-
inflamed. To test the hypothesis that the innate immune response is inherently 
dysregulated in CD patients, we compared mRNA levels in the colon and ileum 
for five potential biomarkers in non-inflamed tissue from CD patients and healthy 
controls (Figure 2.1 b and c). Levels of RelA, A20, and TNF mRNA were 
significantly lower in non-inflamed colon mucosa of CD patients than in normal 
controls. Expression of pIgR in colon mucosa was highly heterogeneous in 
normal controls and was not significantly different from CD patients. However, 
the observation that many CD patients had low pIgR expression suggested that 
this biomarker might be used to identify a subset of CD patients with deficient 
pIgR-mediated IgA transport. IL-8 expression was extremely low in the majority 
of normal controls and CD patients. However, elevated IL-8 expression in some 
CD patients suggested that this biomarker could be useful in a multifactorial 
analysis of gene expression. There were no significant differences in expression 
in the ileum mucosa between normal controls and CD patients for any of the five 
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biomarkers, suggesting that dysregulated expression of RelA, A20, and TNF may 
be a unique feature of the large bowel in CD. To determine whether expression 
of these biomarkers varies between the colon and ileum, paired biopsies (within 
the same individual) were analyzed from 19 normal controls (Figure 2.2 a) and 
22 CD patients (Figure 2.2 b). Expression of pIgR was higher in the colon than in 
the ileum of both normal controls and CD patients, likely due to enhanced TLR 
signaling from greater numbers of commensal bacteria. 34 We have previously 
reported that pIgR expression is significantly higher in the colon than in the ileum 
in mice and is reduced in mice with deficient TLR signaling. 35 Expression of RelA 
was slightly but significantly higher in the colon than in the ileum of CD patients, 
but not of normal controls. No differences in expression of A20, TNF, or IL-8 
were observed between the colon and ileum of either normal controls or CD 
patients. We conclude that regional differences in gene expression between the 
colon and ileum do not account for the observation that dysregulated expression 
of RelA, A20, and TNF in CD patients was restricted to the large bowel.  
To test the hypothesis that local inflammation influenced biomarker expression, 
we analyzed paired biopsies of non-inflamed and inflamed colon mucosa from 17 
CD patients (Figure 2.3 a). Remarkably, there were no significant differences in 
mRNA levels for any of the five biomarkers, suggesting that the observed 
dysregulation of gene expression in CD patients was an inherent condition of the 
colon mucosa, and not secondary to local inflammation. Because access to the 
ileum during colonoscopy was limited to the terminal 10 – 20 cm, we were only 
able to obtain a single biopsy of the ileum mucosa per individual. Accordingly, 
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each CD patient was classified as having either non-inflamed or inflamed ileum, 
even though regional differences in inflammation could have existed in other 
parts of the small bowel. Interestingly, no differences in the expression of RelA, 
A20, pIgR, or TNF were observed among different CD patients with or without 
ileal inflammation (Figure 2.3 b). However, expression of IL-8 was significantly 
elevated in mucosa of CD patients with visible inflammation in the terminal ileum, 
suggesting that this gene may be a biomarker for acute ileal disease. 
 
Multifactorial analysis of five biomarkers defines molecular phenotypic subsets in 
CD  
The heterogeneous patterns of gene expression in both normal controls and CD 
patients suggested that a multifactorial scheme might be more robust than 
individual biomarkers for classifying molecular phenotypes. Principal component 
analysis (PCA) is a statistical approach that is used to reduce the number of vari-
ables in a complex data set and to classify relationships between variables. 36 A 
recent study utilized PCA to identify a subset of IBD patients with significant 
abnormalities in the composition of the colonic microbiota. 37 We used PCA to 
classify our study cohort (including both normal controls and CD patients) into 
molecular phenotypic subsets based on expression of RelA, A20, pIgR, TNF, and 
IL-8 mRNA in non-inflamed intestinal mucosa. The first step in this analysis was 
to examine patterns of correlated expression among the five potential biomarkers 
(Figure 2.4 a). In the colon, highly significant correlations were observed among 
the expression levels of RelA, A20, pIgR, and TNF, consistent with the function 
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of NF- kB in inducing transcription of the A20, pIgR, and TNF genes. Expression 
of TNF but not RelA was positively correlated with IL-8, suggesting that TNF may 
promote IL-8 gene transcription through a RelAindependent mechanism. In the 
ileum, A20 expression was positively correlated with RelA and TNF, but RelA 
and TNF were not correlated with each other. In contrast to the colon, IL-8 
expression was positively correlated with pIgR but not TNF.  
Principal component analysis was used to reduce the five variables to two factors 
or principal components (PCs) (Figure 2.4 b). The χ² analysis demonstrated that 
most of the variability in the data set could be described by PC1 and PC2 (P < 
0.0001 for the colon and P = 0.0255 for the ileum). On the basis of colon gene 
expression, PC1 was strongly weighted toward RelA, A20, and pIgR, with an 
intermediate weight for TNF and a negative weight for IL-8 (see Factor tables in 
Figure 2.4 b). PC2 was strongly weighted toward TNF and IL-8, with a low weight 
for RelA and negative weights for A20 and pIgR. For ileum gene expression, PC1 
was strongly weighted toward RelA, A20, pIgR, and TNF and weakly weighted 
toward IL-8. PC2 was strongly weighted toward IL-8, weakly weighted toward 
pIgR and TNF, and negatively weighted toward RelA and A20. Each normal 
control and CD patient was assigned a score for PC1 and PC2 based on the sum 
of weighted expression levels for all five biomarkers (see Methods). Scatter plots 
of the scores for PC1 vs. PC2 demonstrated that individuals could be classified 
into three subsets based on colon or ileum gene expression (Figure 2.4 c). Set 1 
is defined as individuals with a high score for PC1 and a low score for PC2, set 2 
is defined as individuals with low scores for both PC1 and PC2, and set 3 is 
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defined as individuals with a high score for PC2. On the basis of colon gene 
expression, 81 % of normal controls were classified into set 1, with8% in set 2 
and 11 % in set 3 ( Figure 2.4 d). On the basis of ileum gene expression, the 
percentages of normal controls in sets 1, 2, and 3 were 57, 38, and 5 %, 
respectively. These findings suggested that high scores for PC1 and low scores 
for PC2, particularly for the colon, define a “normal” molecular phenotype. In 
contrast, 42 % of CD patients were classified in set 1 based on colon gene 
expression, with 45 % in set 2 and 13 % in set 3. On the basis of ileum gene 
expression, the percentages of CD patients in sets 1, 2, and 3 were 33, 45, and 
22 % , respectively.  
Patterns of colon gene expression differed significantly for CD patients classified 
into the three molecular phenotypic subsets (Figure 2.5). Individuals in set 2 had 
significantly reduced expression of RelA, A20, pIgR, and TNF compared to 
individuals in set 1 (the “normal” phenotype). Individuals in set 3 had significantly 
reduced expression of RelA, A20, and pIgR, normal expression of TNF, and 
elevated expression of IL-8. On the basis of these findings, we propose that CD 
patients in set 2 have an inherent deficiency in innate immunity in the colon 
mucosa. CD patients in set 3 had selected features of innate immunodeficiency 
(reduced RelA, A20, and pIgR), but elevated IL-8 expression in this group was 
suggestive of acute inflammation. Classification of individuals based on ileum 
gene expression was less informative than for the colon. CD patients in ileum set 
2 had some evidence of innate immunodeficiency (reduced levels of RelA and 
A20), but expression of pIgR and TNF was normal. CD patients in ileum set 3 
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had elevated IL-8 expression, but no evidence of innate immunodeficiency. We 
conclude that RelA, A20, pIgR, TNF, and IL-8 are potentially useful biomarkers 
for classification of CD patients into molecular phenotypic subsets based on gene 
expression in non-inflamed colon mucosa. Accordingly, we compared clinical 
findings in CD patients distributed into the three colon subsets.  
 
Aberrant localization of pIgR and SIgA in a subset of CD patients 
Deficient pIgR expression in mice has been associated with reduced transport of 
SIgA into the colon lumen and elevation of serum IgA. 25,26We observed that 
serum IgA levels tended to be lower in CD patients than in normal controls 
(Figure 2.6 a), but given the overall heterogeneity, this difference did not achieve 
statistical significance. However, serum IgA levels were significantly elevated in 
CD patients in set 2 (Figure 2.6 b), who had decreased expression of pIgR in the 
colonic mucosa (Figure 2.5 a). Serum IgA levels also appeared to be elevated in 
CD patients in set 3, although due to the relatively small number of individuals in 
set 3 the difference from set 1 was not statistically significant. To examine 
whether reduced pIgR-mediated transport of IgA contributed to the elevation in 
serum IgA, we compared the localization of pIgR and IgA in colonic biopsies from 
a normal individual in set 1 and from a CD patient in set 2 (Figure 2. 6 c). In the 
normal colon mucosa, pIgR and IgA were colocalized at the basolateral surface, 
within the cytoplasm, and at the apical surface of epithelial cells, consistent with 
normal transport of IgA. In the lamina propria, IgA was observed in association 
with plasma cells, but no pIgR was detected. In contrast, staining for pIgR was 
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markedly reduced in epithelial cells of non-inflamed mucosa from the set 2 CD 
patient, and there was reduced evidence of transepithelial transport of IgA. In 
addition, more IgA was observed in the lamina propria, compared with the normal 
control. A punctuate border of colocalized pIgR / SC and IgA at the apical surface 
of the epithelium most likely represented SIgA bound to the mucus layer. In the 
inflamed mucosa from the same CD patient, dense colocalization of IgA and 
pIgR / SC in the lamina propria was suggestive of deposition of SIgA along the 
basement membrane. Leakage of excess IgA (either free or bound to SC) from 
the lamina propria into the systemic circulation could account in part for the 
elevated levels of serum IgA in set 2 CD patients.  
 
Correlations between molecular phenotypes and clinical outcomes of CD patients  
A review of the clinical histories of CD patients in this cohort indicated that, in 
general, patients in set 1 tended to have mild disease and good responses to 
therapy; patients in set 2 had moderate to severe disease and poor responses to 
immunosuppressive and anti-TNF therapy; and patients in set 3 had acute 
disease that responded promptly and durably to therapy.  
Although young age at diagnosis of CD has been reported to be associated with 
more severe disease,38 we observed no differences among the three subsets in 
age at diagnosis (Mann – Whitney test, P>0.05). We did find that set 3 patients 
tended to be more recently diagnosed, independent of the age at diagnosis 
(Figure 2.7). Set 3 patients also had elevated serum C-reactive protein, a marker 
of acute inflammation in CD10   (Figure 2.7). These data suggest that some CD 
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patients may present initially with acute inflammation (set 3), but the inherent 
innate immunodeficiency characterized by reduced expression of RelA, A20, and 
pIgR (and likely other genes) results in a failure to resolve the underlying trigger 
of inflammation. Over time, these patients may progress from acute to chronic 
inflammation, characteristic of set 2.  
Recent evidence suggests that inflammatory mediators produced by visceral 
adipose tissue may promote intestinal inflammation in CD. 39 However, we observed 
no differences in body mass index among molecular phenotypic subsets, 
indicating that excess body fat did not influence expression of the biomarkers we 
analyzed. There were also no significant differences among subsets in Harvey–
Bradshaw index of disease activity 40 at the time of colonoscopy, suggesting that 
subjective evaluation of disease activity at one point in time may not be 
informative with respect to the underlying molecular pathogenesis of the disease. 
Other clinical characteristics that did not affect distribution of CD patients into 
molecular phenotypic subsets included gender, smoking behavior, and disease 
location (colon vs. ileum, or both) (Table 2.1).  
Crohn’s disease patients with an inflammatory or stricturing phenotype (Montreal 
classification41) were evenly distributed among the three molecular phenotypic 
subsets (Table 2.1). In contrast, patients with penetrating disease were 
significantly biased toward set 3 and away from set 2 (P = 0.019). Given that only 
three patients in our cohort had penetrating disease, these data must be 
interpreted with caution. However, the possibility that the combination of innate 
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immunodeficiency and acute inflammation that characterizes set 3 may 
predispose patients to penetrating disease deserves further investigation.  
          Only one patient in our cohort (classified in set 1) was homozygous for the 
L1007fsinsC polymorphism in the NOD2 gene, which confers increased risk for 
CD 42 (Table 2.1). Several additional patients were heterozygous for other NOD2 
polymorphism - but these did not affect their distribution among the molecular 
phenotypic subsets. These findings suggest that the abnormalities in innate 
immunity identified by our classification scheme are unrelated to NOD2 
polymorphisms.  
We next investigated whether the medications that CD patients were receiving at 
the time of biopsy affected their patients among the three subsets (Table 2.2). 
We conclude that the observed abnormalities in mucosal gene expression in sets 
2 and 3 reflected an underlying pathology characteristic of each individual, and 
did not result from acute effects of medications they were receiving at the time of 
biopsy. This finding does not rule out the possibility that medications received 
earlier in the course of the disease may have had long-term effects on mucosal 
gene expression.     
 
DISCUSSION  
Signature biomarkers for CD  
Here we describe a molecular classification scheme, based on expression of 
RelA, A20, pIgR, TNF, and IL-8 in the colon mucosa, which identifies unique 
phenotypic subsets of CD patients. Several findings support the concept that 
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these are molecular phenotypes. The χ2 analysis revealed no significant effect of 
any medication on distribution of CD “signature biomarkers” for CD. First, 
biomarker expression appeared to be an inherent characteristic of each CD 
patient, and was not affected by local variations in tissue inflammation or current 
medications. Second, these biomarkers identified a potential state of innate 
immunodeficiency in the majority of CD patients in our cohort, accompanied by 
chronic (set 2) or acute (set 3) mucosal inflammation. Third, classification of CD 
patients into these molecular phenotypic subsets was predictive of disease 
behavior and responses to therapy. Our findings provide strong support for 
prospective studies of this molecular classification scheme in a larger population 
of CD patients.  
 
A model for dysregulated innate immunity in CD  
The pathology of CD arises from an imbalanced immune response to exogenous 
and endogenous molecular cues. Traditionally, CD has been viewed as an 
exaggerated inflammatory response to microbial antigens caused by a 
dysregulated adaptive immune response. However, recent evidence suggests 
that the primary defect in CD may actually be a deficient innate immune 
response in the intestinal mucosa, resulting in inadequate clearance of bacteria 
and other foreign material from the lamina propria and generation of a chronic 
inflammatory state. 8,9 The intestinal epithelium is a crucial player in maintaining 
this balance, going beyond the simple role of a physical barrier to orchestrate the 
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physiological inflammatory response and the innate immune response to dietary 
and microbial antigens.  
We propose that expression of RelA, A20, pIgR, TNF, and IL-8 may be useful for 
assessing innate immune function in the colon mucosa. A model describing the 
activities of these molecules in normal and diseased mucosa is presented in 
Figure 2.8. In healthy mucosa, cross talk between epithelial cells and 
constituents of the commensal microbiota is essential for maintaining normal 
expression of the RelA subunit of NF- kB. Constitutive low-level activation and 
nuclear translocation of NF- kB result in physiological inflammation, 
characterized by high expression of pIgR and other proteins involved in epithelial 
polarity and function, as well as moderate expression of TNF, IL-8, and other 
effectors of innate immunity. Coordinate expression of negative regulatory 
molecules such as A20 protects epithelial cells from excessive activation and 
nuclear translocation of NF- kB. IgA produced by plasma cells in the lamina 
propria is transported across the epithelial layer by pIgR, thus promoting 
intracellular and extracellular neutralization of microbes and their products and 
regulating immune effector molecules such as IL-8. 23, 24, 43 Reduced expression 
of RelA in the colon mucosa of some CD patients may compromise the ability of 
epithelial cells to mount a physiological inflammatory response to the commensal 
microbiota. Reduced expression of pIgR could inhibit normal transport of IgA, 
resulting in diminished regulation of microbial products and IL-8, compromised 
barrier function, and deposition of SIgA complexes in the lamina propria. Low 
mucosal expression of RelA may also predispose CD patients to periodic flares 
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of pathological inflammation, due to reduced expression of negative regulators 
such as A20, diminished anti-inflammatory activity of SIgA, increased access of 
microbial antigens to the lamina propria, activation of macrophages and 
generation of an adaptive immune response.  
 
Protective roles for NF- kB / RelA in the intestinal epithelium  
Association of NF- kB signaling with induction of pro-inflammatory cytokines in T 
cells and inflammatory cells such as macrophages and neutrophils has 
supported the use of therapies designed to inhibit activation of NF- kB. 1. When 
considering these therapeutic approaches, it should be kept in mind that 
physiological NF- kB signaling is important for maintenance of intestinal 
homeostasis. It has recently been reported that selective inhibition of NF- kB 
activation in intestinal epithelial cells, by targeted deletion of genes encoding 
subunits of the IkB-kinase complex, actually increases the susceptibility of mice 
to experimental colitis. 13,14 A critical role of the RelA subunit of NF-kB in intestinal 
homeostasis was highlighted by the recent report that mice with a targeted 
deletion of Rela in intestinal epithelial cells exhibited reduced expression of pro-
restitution genes, elevated epithelial apoptosis and proliferation, and increased 
susceptibility to chemically induced colitis.15  Our data suggest that reduced 
expression of the RelA subunit of NF- kB in the gut mucosa, with concomitant 
downregulation of key target genes, may be a contributing factor for the 
development of CD in humans.  
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 NF-kB signaling in the intestine is kept under tight control by a complex network 
of negative regulatory molecules, many of which are target genes of NF-kB. 17  To 
represent this group of negative regulators in our panel of biomarkers, we 
analyzed expression of A20, a ubiquitin-editing enzyme that downregulates NF- 
kB signaling initiated by pro-inflammatory cytokines and TLRs. 44 A20 null mice 
have been shown to develop severe intestinal inflammation, 18 suggesting that 
A20 and other negative regulators may fulfill the role of a “brake” and set the 
threshold for NF- kB activation. We consistently observed down-regulation of 
mucosal A20 expression in CD patients, which may hamper their ability to 
regulate pathological NF-kB activation induced by acute inflammatory responses. 
Significantly, we found that A20 levels did not increase in inflamed regions of the 
colon in CD patients (Figure 2.3). Paradoxically, CD may be characterized both 
by a defect in physiological NF- kB signaling and by a reduced capacity to 
regulate pathological NF-kB signaling.    
 
Compartmentalization of IgA in the intestinal epithelium is crucial for barrier 
function  
Compartmentalization of IgA antibodies in the gut enhances barrier function by 
allowing a local antigen-specific response to commensal microorganisms without 
stimulating potentially inflammatory systemic immune responses. 20 We observed 
that reduction of pIgR expression in some CD patients (set 2) led to reduced 
transport of IgA and accumulation of dense membranous deposits of SIgA 
(Figure 2.6). Elevated serum IgA levels in this group of CD patients could have 
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resulted from leakage of IgA from the lamina propria into the systemic circulation, 
which has been reported in pIgR-deficient mice. 25,26  Elevated serum IgA could 
also result from deficient epithelial barrier function and access of the commensal 
microbiota to the lamina propria, resulting in a loss of tolerance and a systemic 
immune response to microbial antigens.  
 
Potential applications of a molecular classification scheme for diagnosis and 
management of CD  
The results of this study support the concept of developing a molecular 
classification scheme for CD based on patterns of gene expression in the colon 
mucosa. Using this scheme, we classified a cohort of CD patients into three 
molecular phenotypic subsets that were generally predictive of clinical findings 
and responses to therapy. It will be important to validate this model in a larger 
cohort and to evaluate the utility of additional biomarkers. Molecular classification 
of CD patients at the time of diagnosis may be helpful in targeting specific 
therapies. For example, patients classified in set 3, with evidence of acute 
inflammation, may respond better to TNF blockers and other biological therapies 
than would patients classified in set 2, who exhibited subnormal expression of 
TNF in the colon mucosa. This classification system may also be useful for 
monitoring the course of the disease and modifying therapy over time. We found 
that recently diagnosed patients were more likely to be classified in set 3, 
whereas patients with longstanding disease were more likely to be classified in 
set 1 or set 2 (Figure 2.7), suggesting that patients may undergo transition over 
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time into different subsets. Our finding of reduced mucosal expression of RelA in 
both set 2 and set 3, as well as the need for physiological NF- kB activation to 
maintain epithelial barrier function, suggests that the application of therapies 
designed to inhibit NF-kB activation should be used with caution. 
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Table Legends 
Table 2. 1 Comparison of clinical characteristics and molecular phenotypes of 
CD patients. Abbreviation: CD, Crohn’s disease. The χ² analysis tested the 
hypothesis that CD patients displaying each of the listed clinical characteristics 
would be distributed among the molecular phenotypic subsets in the same 
proportions in which the entire cohort of CD patients was distributed, i.e., set 1: 
set 2: set 3; 22:24:7 (see Figure 2.4 d). 
  
Table 2.2. Effects of medications at the time of biopsy on molecular phenotypes 
of CD patients Abbreviation: CD, Crohn’s disease. The χ² analysis tested the 
hypothesis that CD patients receiving each of the listed medications would be 
evenly distributed among the molecular phenotypic subsets in the same 
proportions in which the entire cohort of CD patients was distributed, i.e., set 1: 
set 2: set 3; 22:24:7 (see Figure 2. 4 d). Medications: 5-ASA: mesalamine; 
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immunosuppressants: azathioprine, 6-mercaptopurine, methotrexate; steroids: 
budesonide, prednisone; anti-TNF: Remicade (infliximab), Humira (adalimumab). 
Some patients were receiving more than one medication at the time of biopsy.  
 
Figure legends 
Figure 2.1 Biomarker expressions in CD patients and normal controls. Patient 
characteristics (a) and gene expression in non-inflamed colon (b) and ileum (c) 
mucosa were compared between CD patients and normal controls. mRNA levels 
were measured by RT-qPCR and normalized to β2-microglobulin mRNA. Data 
are displayed as histograms to illustrate the heterogeneity in expression of 
individual biomarkers. Dashed lines indicate median expression levels for each 
group. Significant differences among groups were tested by Mann – Whitney 
non-parametric analysis; P-values are listed for each comparison of normal 
controls vs. CD patients. CD, Crohn’s disease; RT-qPCR, real-time quantitative 
PCR.  
 
Figure 2.2 Comparison of gene expression in colon and ileum. Paired biopsies 
were obtained from non-inflamed mucosa of the colon and ileum for 19 normal 
controls (a) and 22 CD patients (b). mRNA levels were measured by RT-qPCR 
and normalized to 2-microglobulin mRNA. Dashed lines indicate the difference in 
median expression levels between colon and ileum for each gene. Significant 
differences among groups were tested by paired sign non-parametric analysis; P- 
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 values are listed for each comparison of colon vs. ileum. CD, Crohn’ s disease; 
RT-qPCR, real-time quantitative PCR  
 
Figure 2.3 Effects of local inflammation on gene expression. mRNA levels were 
measured by RT-qPCR and normalized to 2-microglobulin mRNA.  
(a) Paired biopsies were obtained from non-inflamed and inflamed colon mucosa 
from 17 CD patients. Dashed lines indicate the difference in median expression                
levels between non-inflamed and inflamed mucosa for each gene. Significant 
differences among groups were tested by paired sign non-parametric analysis; P-
values are listed for paired comparisons between inflamed vs. non-inflamed 
colon mucosae. (b) Histograms of gene expression in inflamed or non-inflamed 
ileum mucosae from different individuals. Because of limited access to the ileum 
during colonoscopy, a single biopsy from the terminal ileum for each CD patient 
was classified as either inflamed or non-inflamed, and paired biopsies could not 
be collected. Significant differences among groups were tested by Mann – 
Whitney non-parametric analysis; P-values are listed for each comparison of 
individuals with inflamed vs. non-inflamed ileum mucosa. CD, Crohn’s disease; 
RT-qPCR, real-time quantitative PCR.  
 
Figure 2. 4  Multifactorial analysis of gene expression patterns. (a) Non-
parametric Spearman correlation analysis of gene expression data from Figure 
2.1 Correlation coefficients (r) and P-values are listed for each comparison. 
Statistically significant correlations (P< 0.05) are shaded. (b) Factor analysis of 
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NF-kB, RelA, A20, pIgR, TNF, and IL-8 mRNA levels in non-inflamed colon and 
ileum mucosa, including both normal controls and CD patients. Weighted factors 
are listed for principal components (PCs) 1 and 2 for each gene. (c) Classification 
of individuals into molecular phenotypic subsets. Scores for PC1 and PC2 were 
calculated for each individual based on the sum of weighted expression levels for 
all five biomarkers (see Methods). Set 1 comprises individuals with a high PC1 
score and low PC2 score. Set 2 comprises individuals with low scores for both 
PC1 and PC2. Set 3 comprises individuals with high scores for PC2. The table 
lists the distribution of normal controls and CD patients among colon and ileum 
subsets. The scatter plots represent the scores for PC1 and PC2 for each 
individual; open circle =normal control; filled circle =CD patient. (d) Distribution of 
individuals into molecular phenotypic subsets based on scores for PC1 and PC2. 
CD, Crohn ’ s disease; IL, interleukin; NF- kB, nuclear factor- kB; PC, principal 
component; pIgR, polymeric immunoglobulin receptor; TNF tumor necrosis 
factor. 
 
Figure 2.5 Comparison of individual biomarker expression in CD patients 
grouped by molecular phenotype. CD patients were classified in sets 1 – 3 by 
principal component analysis, as described in Figure 2.4. mRNA levels in colon 
(a) and ileum (b) mucosa were measured by RT-qPCR and normalized to 2-
microglobulin mRNA. Gene expression levels for sets 1, 2, and 3 were compared 
by non-parametric Mann – Whitney analysis and are expressed as median + 
median absolute deviation. Asterisks indicate that gene expression in set 2 or 3 
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is different from that in set 1 (P< 0.05). CD, Crohn’s disease; RT-qPCR, real-time 
quantitative PCR. 
 
Figure 2.6 Serum IgA levels and localization of pIgR and IgA in colonic mucosa 
of normal controls and CD patients. (a) Histograms of serum IgA levels in normal 
controls and CD patients. Dashed lines indicate median levels for each group. 
Differences in serum IgA levels for normal controls vs. CD patients were tested 
by Mann – Whitney non-parametric analysis. (b) Comparison of serum IgA in CD 
patients classified in sets 1 – 3 by principal component analysis, as described in 
Figure 2.4. Serum IgA levels in sets 1, 2, and 3 were compared by non-
parametric Mann – Whitney analysis and are expressed as median + median 
absolute deviation. An asterisk indicates that gene expression in set 2 or 3 is 
different from that in set 1 (p < 0.05).  (c) Localization of pIgR / SC and IgA in 
colonic mucosa by immunofluorescence. Representative images are shown from 
a normal subject (representing set 1) or matched biopsies from visibly inflamed 
and non-inflamed regions of the colon from a CD patient with low pIgR mRNA 
expression (representing set 2). Red staining indicates binding of antibody to 
human SC and green staining indicates binding of antibody to human IgA. All 
samples were counterstained with DAPI to visualize nuclei. Stained tissue 
sections were imaged with a × 20 objective; the bottom panels are enlargements 
of the designated regions from merged images. CD, Crohn’s disease; DAPI, 4 ', 
6-diamidino-2-phenylindole dihydrochloride; E, epithelium; LP, lamina propria; 
pIgR, polymeric immunoglobulin receptor; SC, secretory component. 
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Figure 2.7 Clinical characteristics of CD patients classified in sets 1 – 3 based on 
colon gene expression. Disease duration is defined as the time from initial CD 
diagnosis to when the mucosal biopsy was collected / each individual. Values for 
sets 1, 2, and 3 were compared by non-parametric Mann – Whitney analysis and 
are expressed as median + median absolute deviation. P-values indicate 
significant differences between CD patients in set 2 and set 3. No significant 
differences were observed between set 1 and sets 2 or 3. CD= Crohn’s disease.  
 
Figure 2. 8 Model for inflammation due to dysregulated mucosal gene expression 
in Crohn’s disease. (a) (1) In normal mucosa, bacterial – epithelial cross talk 
upregulates expression and activation of NF- kB (RelA) and expression of 
downstream targets (A20, pIgR, and TNF). Modulation of these responses by 
A20 and other negative regulators limits the “physiologic inflammation.”  (2) IgA 
secreted by lamina propria plasma cells binds to pIgR on the basolateral surface 
of epithelial cells and is transported to the apical surface. (3) During transport, 
SIgA facilitates clearance of bacterial antigens and inflammatory chemokines. (4) 
SIgA promotes immune barrier function at the luminal surface. (b) (1) Defective 
expression of NF- kB and downstream genes by epithelial cells in CD. (2) 
Abnormal deposits of SIgA in the lamina propria. (3) Failure of IgA-mediated 
clearance of antigens and IL-8 due to defective epithelial transport. (4) Reduced 
SIgA at the luminal surface results in diminished barrier function. (5) Excess SIgA 
in the lamina propria enters the systemic circulation. (6) Chronic inflammation 
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with increased IL-8 and influx of neutrophils and macrophages. CD, Crohn’ s 
disease; IL, interleukin; NF- kB, nuclear factor- kB; pIgR, polymeric 
immunoglobulin receptor; SIgA, secretory antibodies of the IgA class; TNF, tumor 
necrosis factor.  
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Table 2.1 Comparison of clinical characteristics and molecular phenotypes of CD 
patients 
  Number of subjects      
  Set 1  Set 2  Set 3      
Factor  Observed  Expected  Observed  Expected  Observed  Expected  
2  P  
Gender  
 Male 7 8.7 9 9.5 5 7.0 2.153 0.341 
 Female 15 13.3 15 14.5 2 4.2 1.413 0.493 
                  
Smoking behavior  
 Smoker 7 6.6 8 7.2 1 2.1 0.684 0.710 
 Non-smoker 15 13.7 13 14.9 5 4.4 0.471 0.790 
                  
Disease location  
 Ileum only 7 5.0 4 5.4 1 1.6 1.413 0.493 
 Colon only 4 4.6 5 5.0 2 1.5 0.276 0.871 
 Ileum+colon 11 12.0 14 13.1 4 3.8 0.154 0.926 
                  
Disease behavior  
Inflammation 
 only 10 8.3 6 9.1 4 2.6 2.078 0.354 
 Stricturing 11 11.6 14 12.7 3 3.7 0.303 0.860 
 Penetrating 1 1.2 0 1.4 2 0.4 7.898 0.019 
                  
NOD2 polymorphisms  
 R702W+/-  4 2.1 0 2.3 1 0.7 4.223 0.121 
 G908R+/-  0 0.4 1 0.5 0 0.1 1.208 0.547 
L1007fsinsC
+/+ 1 0.4 0 0.5 0 0.1 1.409 0.494 
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Table 2.2 Effects of medications at the time of biopsy on molecular phenotypes 
of CD patients 
  Number of subjects      
  Set 1  Set 2  Set 3      
Medication  Observed  Expected  Observed  Expected  Observed  Expected  2  P  
5-ASA                  
 No 10 13.3 17 14.5 5 4.2 1.388 0.500 
 Yes 12 8.7 7 9.5 2 2.8 2.114 0.347 
                  
Immuno -
suppressants                  
 No 14 12.0 14 13.1 1 3.8 2.469 0.291 
 Yes 8 10.0 10 10.9 6 3.2 2.983 0.225 
                  
Steroids                  
 No 13 14.9 18 16.3 5 4.8 0.442 0.802 
 Yes 9 7.1 6 7.7 2 2.2 0.937 0.626 
                  
Anti-TNF 
biologics                  
 No 16 17.8 21 19.5 6 5.7 0.330 0.848 
 Yes 6 4.2 3 4.5 1 1.3 1.417 0.492 
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 Figure 2.1 Biomarker expressions in CD patients and normal controls. 
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Figure 2.2  Comparison of gene expression in colon and ileum. 
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Figure 2.3 Effects of local inflammation on gene expression 
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Figure 2.4 Multifactorial analysis of gene expression patterns 
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Figure 2.5 Comparison of individual biomarker expression in CD patients 
grouped by molecular phenotype 
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Figure 2.6 Serum IgA levels and localization of pIgR and IgA in colonic mucosa 
of normal controls and CD patients 
61 
 
 
Figure 2.7 Clinical characteristics of CD patients classified in sets 1 – 3 based on 
colon gene expression 
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Figure 2.8  Model for inflammation due to dysregulated mucosal gene expression 
in Crohn’s disease 
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Chapter Three  
The content of Chapter 3 has been published in the Journal of Digestive 
Diseases and Sciences. Permission to reproduce this material has been obtained 
from the Springer Publishing House. 
 
ADIPONECTIN AND PLANT DERIVED-MAMMALIAN ADIPONECTIN - 
HOMOLOG EXERT A PROTECTIVE EFFECT IN MURINE COLITIS 
 
Synopsis 
Background: Hypoadiponectinemia has been associated with states of chronic 
inflammation in humans. Mesenteric fat hypertrophy and low adiponectin have 
been described in patients with Crohn’s disease. We investigated whether 
adiponectin and the plant-derived homolog - Osmotin - are beneficial in a murine 
model of colitis. 
Methods: C57BL/6 mice were injected (i.v.) with an adenoviral construct 
encoding the full-length murine adiponectin gene (AN+DSS) or a reporter - LacZ 
(Ctr and V+DSS groups) prior to DSS colitis protocol. In another experiment, 
mice with DSS colitis received either Osmotin (Osm+DSS) or saline (DSS) via 
osmotic pumps. Disease progression and severity were evaluated using body 
weight, stool consistency, rectal bleeding, colon lengths, and histology. In vitro 
experiments were carried out in bone marrow derived dendritic cells. 
Results: Mice overexpressing adiponectin had lower expression of 
proinflammatory cytokines (TNF, IL-1β), adipokines (angiotensin, osteopontin), 
64 
 
and cellular stress and apoptosis markers. These mice had higher levels of IL-10, 
alternative macrophage marker – arginase 1 and leukoprotease inhibitor.  The 
plant adiponectin homolog Osmotin similarly improved colitis outcome and 
induced robust IL-10 secretion. LPS induced a state of adiponectin resistance in 
dendritic cells that was reversed by treatment with PPARγ agonist and retinoic 
acid. 
Conclusion: Adiponectin exerted protective effects during murine DSS colitis. It 
had a broad activity that encompassed cytokines, chemotactic factors as well as 
processes that assure cell viability during stressful conditions. Reducing 
adiponectin resistance or using plant derived adiponectin homologs may become 
therapeutic options in IBD. 
 
Introduction 
       Inflammatory Bowel Diseases, Crohn’s Disease and Ulcerative colitis are 
chronic relapsing conditions that result from an inappropriate response to gut 
microbiota 99. Crohn’s disease patients develop transmural inflammation of the 
gastrointestinal tract, which may lead to complications such as strictures and 
perforations.  Recent advances in metabolic and cardiovascular diseases have 
led to a paradigm shift in which adipose tissue has been upgraded from an 
energy depot to a source of immunomodulatory cytokines (adipokines). In his 
original description of the disease, Burril Crohn directed the attention toward the 
characteristic mesenteric fat change100. Accumulation of mesenteric fat appears 
to be specific for Crohn’s disease, and occurs from the onset of disease37. Fat 
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wrapping has been defined as fat hypertrophy extending from the mesenteric 
attachment with > 50% coverage of the intestinal surface101. It occurs in both the 
small and large bowel, and correlates with transmural inflammation, ulceration, 
stricture formation, increased mesenteric wall thickness, and decreased internal 
bowel diameter101.  Fat wrapping and mural thickening is associated with 
mucosal ulceration in 86% 102 and with strictures in 46% of patients 102.  
Importantly, it   was noted in 100% of patients undergoing resection, and 
correlated with the degree of acute and chronic inflammation103.  
           Functional pattern recognition receptors (PPRs) have been recently 
identified in nonimmune cells like adipocytes, as well. Therefore, by expressing 
functional cell membrane PPRs like Nucleotide-binding oligomerization domain 
containing 2 (NOD2), cluster of differentiation 14 (CD14), toll-like receptors 
(TLR2, TLR4, and TLR5) the adipose tissue can also, respond to bacterial wall 
products, developing a proinflammatory phenotype104. When we consider the fact 
that preadipocytes may differentiate towards the macrophage line and that NOD2 
mutation is strongly associated with Crohn’s disease, the adipose tissue 
becomes a dynamic player for the disease phenotype.  In addition, TLR signaling 
leads to decreased  expression of the adipose tissue anti-inflammatory adipokine 
– adiponectin and lowers its receptors104. It also promotes free fatty acid 
accumulation that act as an endogenous TLR4 ligand. Therefore, a vicious cycle 
is established that potentially induces a state of hypoadiponectemia and/or 
adiponectin resistance.  Considering that adiponectin can bind and neutralize 
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lipopolysaccharide (LPS) the hypoadiponectemia can lead to secondary 
activation of the immune system105.  
              Angiotensinogen is the precursor of the inflammatory adipokine 
angiotensin and is secreted by the adipocytes. Angiotensinogen negatively 
regulates adiponectin expression106. In addition, epithelial cells and macrophages 
produce angiotensinogen-converting enzyme (ACE) that catalyze the conversion 
of the pro-inflammatory peptide - angiotensin 107-108. In turn, angiotensin 
promotes Th1 type cytokine production and development of colitis 81. Hence, 
another vicious inflammatory circle may occur between adipocytes, epithelial 
cells and macrophages. In contrast, agonists of peroxisome proliferator-activated 
receptor gamma (PPARγ), a common signature marker in the early 
developmental phase of both adipocytes and macrophages induce both 
adiponectin and adiponectin receptors109. Rosiglitazone, a PPARγ agonist has 
been shown to be beneficial in human Inflammatory Bowel Disease and 
experimental colitis110.  
              Obesity, a state of hypoadiponectemia, is associated with more severe 
Crohn’s disease and atherosclerosis. Interestingly,  defective macrophage 
function and  autophagy has been described in both conditions111-112. Autophagy-
related protein 16 (ATG16L1) upregulate adiponectin expression in Paneth cells 
and mutations in this gene is associated with Crohn’s disease29. Mice ATG16L1 
hypomorphic have defective autophagy processes, possibly because of impaired 
anti-microbial peptides production29. Due to the fact that gut microbiota 
suppresses the epithelial expression of fasting-induced adipose factor (FIAF), 
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that promotes triglyceride accumulation, the bacterial-epithelial crosstalk could 
alter adipose mass, and by extension the balance of adipokines and cytokines113.  
                Current studies regarding the adiponectin role in colitis are 
controversial. We hereby, show that adiponectin treatment ameliorates colitis in a 
murine DSS model. Furthermore, we demonstrate that adiponectin alters the 
balance of key regulatory cytokines and adipokines relevant for both 
experimental and human disease. In addition, we propose that a plant derived 
adiponectin homolog may be considered as a viable and accessible IBD 
treatment.  
 
Materials and Methods 
Materials 
99.9% pure Dextran Sulfate Sodium (DSS) was purchased from MP Biomedicals, 
Santa Ana, CA. Adiponectin adenovirus was a generous gift from Dr Jerry 
Olefsky, Loyola University, CA. Osmotin was purified from salt adapted cultured 
tobacco cells as described [36]. No contaminants were detected in the osmotin 
preparation by a combination of 2DGE and mass spectrometric methods. The 
endotoxin content was <0.03 EU/mg protein. 
 
DSS - induced colitis and sample collection 
Male, 3 months old C57BL/6 (Jackson Laboratory, n = 6 mice/group) were 
randomly divided into 3 groups, as described in treatment protocols below. All 
groups of mice were housed in a pathogen-free environment with free access to 
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food and water. Colitis was induced by administration of 3.5% (wt/vol) DSS in 
water for a week, followed by 3 days of water only. Body weight, stool 
consistency and rectal bleeding were monitored daily.  On day ten, mice were 
euthanized with ketamine/xylazine (100/10 mg/kg i.p.) for blood and tissue 
harvest. The colons were removed and perfused with phosphate-buffered saline 
(PBS - pH 7.4), and measured. Half of each colon was fixed in RNAlater 
(Qiagen), and stored at -20°C. The other half was made in a “swiss roll”, cut and 
fixed in 10% buffered formalin (Sigma Chemical). The Animal Care and Use 
Committee at the University of Kentucky approved all procedures.  
 
 Adiponectin overexpression 
The control (Ctr) and V+DSS mice were intravenously (i.v.) injected with 
adenovirus suspension (2x 108 pfu, 0.1ml per mouse) carrying the reporter gene 
LacZ (β-Galactosidase).  Mice in the AN+DSS were intravenously injected with 
an adenovirus suspension (2X108 plaque forming units (pfu), 0.1ml per mouse) 
carrying the murine adiponectin gene.  The Ctr group had only water while the 
V+DSS and AN+DSS groups were fed DSS in the drinking water. All groups 
received the above i.v treatments 3 days prior to DSS colitis protocol.  Blood 
samples were taken at the end of the study to measure the adiponectin plasma 
level using an enzyme- linked immunosorbent assay (ELISA- mouse cytokine 
panel – LINCOplex, Millipore, Billerica, MA) 
 
Treatment with the mammalian adiponectin homolog - osmotin  
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To assess the role of an adiponectin homolog in the treatment of IBD, male, 3 
months old C57BL/6 (Jackson Laboratory, n = 8 mice/group) were divided into 
control (Ctr) group that received phosphate buffered saline only, a DSS group 
that received saline and DSS (DSS), and a group that received osmotin (73 
ug/Kg/h) and DSS (OSM+DSS). All treatments (saline & Osmotin) were delivered 
for 2 weeks using Alzet mini-osmotic pumps (Durect Corp., Cupertino, CA). The 
pumps were implanted subcutaneously in the suprascapular area under sterile 
conditions. They ensured constant delivery of drug during the experiment. During 
the last 10 days, all mice except the Ctr group, received DSS in the drinking 
water for 7 days, followed by water for 3 days. Mice were euthanized with 
ketamine/xylazine and examined for macro and histopathological abnormalities. 
The osmotic pumps were removed and the residual volume was determined. 
Blood was collected for Adiponectin and IL10 measurements by ELISA (mouse 
cytokine panel – LINCOplex, Millipore, Billerica, MA). 
 
Histologic analyses and Proliferating Cell Nuclear Antigen (PCNA) assay 
Formalin fixed colons were embedded in paraffin. From these, serial sections (5 -
7 μm) were stained with hematoxylin and eosin. A pathologist blinded to the 
group allocation assessed the severity of colitis as described elsewhere114.  The 
sections were deparaffinized and treated with Antigen Retrieval Solution (DAKO, 
Carpinteria, CA) followed by incubation in 0.3% H2O2-methanol for 10 min, and 
wash. Sections were incubated in normal blocking serum for 90 min followed by 
overnight incubation in primary antibody, NCL-PCNA (1:200) (Novocastra, Leica 
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Microsystems) at 4°C. The biotinilated secondary antibody ([Elite ABC kit, 
Vector) was then applied for 2 hours. The slides were counterstained with Methyl 
Green (DAKO). Images were taken with an Olympus BX51 microscope (Olympus 
America, Inc.) at 20x magnification. 
  
Analysis of mRNA gene expression levels in mouse colonic tissue 
Total RNA was purified using MagnaPure Compact RNA Isolation Kit (Roche) 
from whole colon tissue and cDNA was obtained using Transcription High Fidelity 
cDNA Synthesis Kit (Roche). Specific mRNA levels were quantified by real time 
reverse transcription-polymerase chain reaction (RT-PCR), using the IQ iCycler 
(Bio-Rad), and SYBR Green qPCR Supermix (Bio-Rad). Primers were designed 
using the Primer 3 software (SourceForge) and the sequences are shown in 
Table 1. The target genes mRNA level were normalized to reference gene 
according to the comparative CT (cycle threshold) method, also referred to as the 
2 ─ ∆∆CT method.  The formula used:  [2─ [Mean 
Cts target – Mean Cts reference)] for each 
sample. For each treatment group the mean ± SE value has been plotted. 
 
Measurement of cytokines in the plasma and the colonic tissue 
At day 10, we measured cytokines in the plasma and the colonic tissue 
homogenate using a bead based immunoassay (Lincoplex) multianalyte 
detection platform (Luminex - Mouse Cytokine Panel). Values are expressed in 
picograms per milliliter and as mean ± SE, n=6 - 8/ group. 
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Western Blot Analyses 
Proteins were extracted from each colon (n=6) per treatment group. Equal 
amounts of protein lysate were separated on 10% SDS-PAGE and transferred to 
nitrocellulose membrane (Bio-Rad, Hercules, CA). We blocked with 5% non-fat 
milk and the blots were washed in TBS-T and incubated with the primary 
antibody at 40C, overnight (mouse anti-β-actin, mouse anti-COX2). Next day, 
blots were washed with TBS-T and incubated for 2h with horseradish peroxidase-
conjugated secondary antibody (goat anti-mouse β-actin or COX2 - Santa-Cruz 
Biotechnology). After careful washing the membrane was visualized by enhanced 
chemiluminescence (ECL) 
 
Bone marrow-derived dendritic cells generation 
A single-cell suspension of bone marrow from femur and tibia bones of C57Bl/6 
mice was obtained by flushing the bones with cell culture media, RPMI 1640 
medium (HyClone, Thermoscientific) supplemented with 10% fetal bovine serum 
(Atlanta Biologicals), L-glutamine, HEPES and Penicillin/Streptomycin 
(Invitrogen). After spinning, the cell pellet was resuspended in dendritic cell 
media (cell culture media supplemented with 20% F10.9 cell supernatant 
containing GMCSF) and plated at a concentration of 4x106 cells. On day 9, both 
adherent and non-adherent fraction of cells were harvested and washed free of 
dendritic cell media. Cells were counted before treating with the appropriate 
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ligands. On day 9, the cultures contained 85% CD11c+ bone marrow-derived 
(BM) dendritic cells (DCs). 
 
Ligand activation of nuclear receptors 
On day 9, BM - DCs were plated at 1X106 cells/ ml in TC-treated 6-well plates 
(Falcon), in 3 replicates per treatment. Cells were incubated for 24 hours with 
10µM Rosiglitazone (R) (Cayman Chemical), 1µM of 9-cis-retinoic acid (RA) 
(Sigma) and their combination. Cells were treated with DMSO or were incubated 
with 1 µg/ml LPS at the time of ligand treatment. At 24 hours, cells were 
harvested and washed extensively to remove residual ligands. RNA was 
extracted using Trizol (Invitrogen) reagent method. cDNA was obtained using 
Transcription High Fidelity cDNA Synthesis Kit (Roche). Specific mRNA levels 
were quantified by real time reverse transcription-polymerase chain reaction (RT-
PCR), using the IQ iCycler [Bio-Rad), and SYBR Green qPCR Supermix (Bio-
Rad). Primers were designed using the Primer 3 software (SourceForge) and the 
sequences are shown in Table 3.1.  
 
 Statistical analysis 
Data are expressed as Mean ± SE. Data were analyzed using one-way analysis 
of variance (ANOVA) (GraphPad Prism 5) followed by Tukey’s test with 
significance accepted at p < 0.05. Body weight data were analyzed by one-way 
ANOVA with repeated measures on time. Significance was accepted at p < 0.05. 
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Results 
The severity of DSS- induced colitis is decreased in mice receiving Adiponectin 
adenovirus 
Viral vector administration did not alter the weight or other clinical parameters 
prior to DSS protocol. At the end of the DSS administration, mice receiving the 
reporter gene and DSS - the V+DSS group - had a significant drop in weight 
(Figure 3.1A, p=0.001), and hematocrit (Figure 3.1B, p=0.02) consistent with 
increased severity. The postmortem exam  of colons from V+DSS mice group 
revealed swollen and shortened colons compared to control (Ctr – water+LacZ) 
and mice receiving Adiponectin adenovirus and DSS (AN+DSS) (Figure 3.1C, 
p=0.01). Microscopically, colitis was mild in the AN+DSS group as compared with 
significant mucosal ulceration, crypt abscesses and altered architecture present 
in V+DSS mice. Proliferating cell nuclear antigen (PCNA) staining revealed a 
significant increase in crypt proliferative activity in AN+DSS group as compared 
to the V+DSS group (Figure 3.1) consistent with a normal epithelial turnover. 
Mice in the AN+DSS group had an increased mRNA expression, colonic and 
plasma level of adiponectin at the end of the study compared with V+DSS and 
Ctr group (Figure 3.2). 
 
Mice that overexpressed adiponectin (AN+DSS) showed decreased pro- 
inflammatory cytokines expression during DSS - induced colitis 
During colitis, inflamed colonic tissue can become a source of inflammatory 
cytokines like tumor necrosis factor (TNFα) interleukin 1 (IL1β), and the key 
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factor in the recruitment of macrophages, the monocyte chemoattractant protein 
(MCP-1).  In our study, adiponectin overexpression had a protective effect and 
led to the downregulation of aforementioned pro-inflammatory cytokines, as well 
as of chemokine (C-C motif), receptor2 (CCR2), the receptor for the MCP1 , as 
compared with control (Ctr) or V+DSS mice groups (Figure 3.3). Consequently, a 
lower expression of MCP1 and CCR2 cytokines could decrease the ability to 
recruit macrophages into the colonic tissue115.  
            
Anti-inflammatory cytokines were increased in mice overexpressing adiponectin 
IL10 is known to limit the extent of intestinal inflammation during colitis by 
inhibiting the macrophage and Th1 cells production of pro-inflammatory 
cytokines116. Administration of adiponectin adenovirus to AN+DSS mice group 
upregulated the expression of the anti-inflammatory cytokine IL10 and its plasma 
level (Figure 3.4A, B) after DSS-induced colonic injury. DSS model of colitis 
leads to significant epithelial damage and recruitment of inflammatory cells 117-118. 
Secretory leukocyte protease inhibitor (SLPi) released by epithelial cells and 
macrophage can limit tissue destruction by neutralizing proteases and 
downregulating pro-inflammatory cytokines 119-120. We observed a robust 
induction of SLPi in mice receiving the adiponectin adenovirus (Figure 3.4D, 
p=0.001). Independent of its anti-protease activity, the SLPi can limit 
macrophage nitric oxide (NO) and TNFα production120. We hypothesized that 
higher IL10 and SLPi expression in adiponectin treated mice will promote M2 
(alternatively activated) macrophages, associated with the repair processes.  The 
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mRNA expression of arginase 1 (Arg 1), a marker of this macrophage phenotype, 
was increased 3 fold in AN+DSS group as compared to Ctr and V+DSS mice 
(Figure 3.4C, p=0.002).   
 
 Adiponectin administration reduces the pro-inflammatory adipokines during DSS 
induced colitis 
Adipose tissue derived hormones like angiotensin II and osteopontin can fulfill 
pro-inflammatory cytokine-like functions 121-122. Both adipokines have been 
shown to promote inflammation in the DSS model of colitis 81,123. Furthermore, 
they are capable of downregulating adiponectin and/or its receptors124. We 
hypothesized that adiponectin treatment will prevent activation of the renin-
angiotensin system (RAS) and osteopontin and complete a regulatory loop that 
protects mice from colitis. Our study showed a 3-fold increase in both 
angiotensinogen (angiotensin precursor) and osteopontin expression in mice 
receiving DSS (Figure 3.5A, 3.5D). Angiotensin II is generated through the 
activity of angiotensin converting enzyme (ACE) while its inflammatory signal 
requires the angiotensin receptor 1 (AT1)125. There was no significant change in 
ACE and AT1 expression during DSS colitis in the V+DSS group receiving the 
reporter gene and DSS (Figure 3.5B, 3.5C) compared to the control group. In 
contrast, higher adiponectin levels in AN+DSS group effectively downregulated 
(3 fold) both ACE and AT1 (Figure 3.5B, 3.5C) and correlated with a protective 
effect from DSS-induced colitis.  
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Adiponectin upregulation in mice with colitis decreased the endoplasmic 
reticulum (ER) stress response and the mediators of apoptosis 
Recent evidence suggests that endoplasmic reticulum (ER) stress is important in 
the initiation and regulation of gut inflammation126.   Human and experimental 
models of  inflammatory bowel diseases are associated with cellular stress due 
to accumulation of misfolded proteins within the colonic epithelium127. 
Endoplasmic reticulum - binding protein (BIP/ Grp78) acts as an intracellular 
sensor and is considered a marker of ER stress. Adiponectin treatment 
decreased BIP mRNA expression in AN+DSS mice (Figure 3.6A) implying a 
lower level of ER stress. In addition, since ER stress response is coupled to the 
cell death program, we investigated the mRNA expression of two pro-apoptotic 
molecules: C/EBP Homologous Protein (CHOP) and Caspase 12 (Casp12). 
There was a 2.5 fold downregulation of the expression of both pro-apoptotic 
genes in the AN+DSS mice compared with V+DSS that expressed the reporter 
gene (Figure 3.6B, C).  Cooperation between cyclooxygenase 2 (COX-2) and 
TLR4 signaling pathway insures optimal proliferation and protection against 
apoptosis in the injured intestine128. In our experiment, adiponectin 
overexpression correlated with decreased disease severity and a three-fold 
increase in colonic COX2 expression (Figure 3.6D, E).  
 
Treatment with the mammalian adiponectin homolog- osmotin- offered similar 
protection against DSS-induced colitis  
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Osmotin, and many of its homologs, functions as defense proteins of the plant 
innate immune system 129.  Osmotin is an adiponectin homolog and can signal 
through adiponectin receptors 1 and 2. Specifically, we showed that osmotin 
could activate the adiponectin target, AMP kinase in mammalian myocytes via 
adiponectin receptors130. In our current experiment, osmotin was delivered via 
mini-osmotic pumps for 2 weeks and colitis was induced by administering 3.5% 
DSS in the drinking water for 7 days. The osmotin treatment group OSM+DSS 
maintained their body weight during DSS injury while the group receiving saline 
(DSS group) had considerable weight loss (Figure 3.7 A). Importantly, none of 
the mice receiving osmotin developed hematochezia, a marker of severe colitis, 
as evidenced by Osm+DSS group hematocrit values in the range of control mice 
(Figure 3.7B). Similar to the adiponectin overexpression experiments, osmotin 
treatment induced a 5 fold increase in plasma level of the anti-inflammatory 
cytokine IL10 (Figure 3.7D). There were no statistically significant differences in 
colonic and plasma levels of adiponectin between the experimental groups (data 
not shown). 
 
PPARγ agonists and retinoic acid reversed the state of adiponectin resistance in 
dendritic cells. 
Bone marrow (BM) derived dendritic cells (DCs) fulfill a major role in the initiation, 
maintenance and propagation of immune responses. In the gut, bacterial stimuli 
such as E. coli lipopolysaccharide (LPS) activate the dendritic cells through toll-
like receptor (TLR) 4 to induce the expression of IL-12 and initiate a Th1 
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response131. PPARγ agonists have been shown to inhibit TLR induced activation 
of DCs132. Furthermore, intestinal epithelial cells release retinoic acid and drive 
the development of tolerogenic subtype of DCs that express the anti-
inflammatory cytokine IL10133. Moreover, the anti-inflammatory adipokine – 
adiponectin - has been shown to induce IL10 release from DCs134. We 
hypothesized that bacterial derived LPS induces a state of adiponectin resistance 
in DCs by downregulating its main receptors – adiponectin receptor 1 & 2. Bone-
marrow derived DCs from C57Bl/6 mice were cultured in the presence or 
absence of LPS (Figure 3.8). There was a 3-fold decrease in both adiponectin 
receptors mRNA expression following LPS exposure (Figure 3.8A, B, C). 
Administration of Rosiglitazone (R) – a PPARγ agonist – and retinoic acid (RA – 
9-cis-retinoic acid) restored the expression of both adiponectin receptors in the 
presence of LPS treatment (Figure 3.8A, B, C). Importantly, the combination of 
PPARγ agonist and retinoic acid [R/RA = Rosiglitazone + 9-cis-retinoic acid) had 
a synergistic effect and more than doubled the secretion of the anti-inflammatory 
cytokine IL10 in DCs (Figure 3.8D).                       
 
Discussion 
 
Adiponectin is unique among adipokines because its circulating levels are 
inversely related to the adipose mass135. Adiponectin gene contains a signal 
sequence, a collagen like domain, and a globular domain similar to the 
complement factor C1q. Our study indicates that adiponectin treatment can 
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significantly ameliorate colonic inflammation in the murine DSS model. 
Overexpression of adiponectin restored normal mucosal architecture and 
reduced the production of potent inflammatory cytokines and adipokines. The 
first evidence for a protective role came from the Nishihara group42. They 
demonstrated that adiponectin treatment protects adiponectin KO mice from DSS 
induced colitis. Meanwhile, no benefit was noted in TNBS model of colitis, 
suggesting the fact that this model might be more dependent on T cells, while the 
adiponectin has a greater influence on the innate immunity. This is also 
supported by the fact that T cells from either wild type or adiponectin KO produce 
similar amounts of pro-inflammatory cytokines IL-6, IL-17, TNFα, and IFNγ upon 
activation with CD3/CD28 antibody136.  
In our experiment the mice overexpressing adiponectin showed a 
reduction in the colonic TNFα, IL1β, as well as colonic and plasma IL-6 (data not 
shown). On the other hand, adiponectin treatment significantly elevated the IL10 
level within the colon and plasma. This observation is in agreement with in-vitro 
studies whereby adiponectin induced macrophage IL10 expression137. In contrast 
to our findings and Nishihara's group, a recent study showed that adiponectin KO 
mice are protected from DSS and TNBS colitis, and adiponectin treatment 
induces inflammation41. The authors have further shown that colonic explants 
from treated mice released more IL-6. Differences in adiponectin KO mice have 
been invoked since only this group showed high basal TNF-α production and 
increased susceptibility to LPS. Several recent studies confirmed that 
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adiponectin effectively blocks LPS induced release of pro-inflammatory cytokines 
and thus, support an anti-inflammatory role 50,138.  
Moreover, a study that compared the outcome of colitis in IL10 KO and 
adiponectin/IL10 double KO found no differences136. It was concluded that 
adiponectin does not play a role in that colitis model. In accordance with our 
experiments, and published data 50,139 we believe that IL10 production is 
paramount for the anti-inflammatory role of adiponectin in colitis. Therefore, the 
results seen in IL10 KO mice are expected. Furthermore, if adiponectin had 
promoted inflammation, the double KO (adiponectin/IL10) mice would have had 
decreased morbidity and mortality compared to IL10 single KO.  
Adiponectin induced IL10 may promote alternative activation of 
macrophages (M2) and resolution of chronic inflammation. We now show that 
adiponectin treatment also resulted in higher colonic expression of arginase-1 a 
marker of such macrophages140. Adipose tissue macrophages from lean mice 
express many genes characteristic of M2 (alternatively activated phenotype) 
macrophages 141, including heparin–binding lectin (Ym1), arginase-1, and IL10. 
Diet-induced obesity (low adiponectin state) decreases expression of these 
genes while increasing expression of those encoding TNF-α and nitric oxide 
synthase (NOS) 2 that are characteristic of classically activated  (M1) 
macrophages 141. Furthermore, AMP-activated protein kinase (AMPK), the kinase 
that translates adiponectin signaling, suppresses proinflammatory responses and 
promotes macrophage polarization to an anti-inflammatory - M2 functional 
phenotype72. Consistent with these observations, macrophages from adiponectin 
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KO mice have lower M2 markers142.  Influx on leukocytes during colitis requires 
coordinated expression of chemokines and their receptors143. In our study, we 
found that adiponectin treatment effectively downregulated both MCP-1 and 
CCR2. It is known that CCR2-/- mice are protected from DSS colitis and have 
increased IL10/TNFα ratio similar to our observations144.  
Leukocytes infiltrate the inflamed gut and breach the epithelial barrier by 
releasing serine proteases. Epithelial cell, in turn, produce secretory 
leukoprotease inhibitor (SLPi) to block their activity as well as exert broad 
antimicrobial properties145. Mice receiving adiponectin, in our experiments had a 
significant upregulation of SLPi expression. This is also important because 
leukocyte proteases can cleave HMW adiponectin – the main anti-inflammatory 
moiety - and increase the amount of globular and LMW forms52. In vitro 
experiments have shown that globular adiponectin induces NF-kB and pro-
inflammatory cytokines, but prolonged exposure blocks further activation. In 
contrast, HMW adiponectin can quickly prevent NF-kB activation53. Thus, 
indirectly, SLPi may modulate its activity at sites of inflammation. Mucosal SLPi 
expression is decreased in Crohn's Disease patients146, and this observation 
adds to the clinical relevance of our study.   
In addition to adiponectin, other adipokines can modulate colitis. We now 
show that adiponectin treatment downregulates the proinflammatory adipokines 
angiotensinogen and osteopontin in experimental colitis. Pharmacological 
blockade of the renin – angiotensin (RAS) system as well as absence of 
osteopontin protects mice from DSS colitis 81,123. In our study, adiponectin had 
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broad effects on the renin-angiotensin system reducing the expression of 
angiotensinogen, angiotensin converting enzyme (ACE) and angiotensin receptor 
1 (AT1). Blockade of angiotensin can increase adiponectin levels and thus a 
regulatory loop may be established. A similar mechanism may operate in the 
case of osteopontin since KO mice have lower adiponectin levels both, under 
basal conditions and during DSS colitis (unpublished observation).  
Adiponectin has a structure similar to complement 1q and TNFα. 
Interestingly, the immune system in plants utilizes thaumatin domain proteins 
such as osmotin, as defense effectors [35]. To date, Osmotin is the only 
thaumatin domain protein that has been reported to act as an adiponectin mimic 
in mammalian cells 130,147. Similar to adiponectin treatment we noticed a 
beneficial effect of Osmotin in DSS colitis. Mice that received a two-week infusion 
of Osmotin showed an improved clinical outcome that correlated with a marked 
elevation of plasma IL10 level. Although Osmotin homologs are ubiquitous in 
plants and occur in significant amounts in edible plant parts, none has been 
examined for adiponectin-like activities. Our results suggest that Osmotin and 
related plant proteins are potentially promising and accessible treatments for 
IBD.  
Decreased adiponectin levels during colitis may be secondary to TLR 
triggered inflammatory response. In the small intestine, the DCs precursors 
differentiate from circulating inflammatory monocytes and acquire mucosal 
functions via micro-environment cues148. During IBD, dysfunctional DCs may act 
by initiating abnormal T cell responses to the enteric environment and release of 
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proinflammatory cytokines. Activators of PPARγ are anti-inflammatory and have 
been proposed as therapeutic agents for the treatment of Th1-type inflammatory 
diseases. For example, rosiglitazone has been shown to enhance the production 
of the anti-inflammatory IL10 from activated human mature monocyte-derived 
dendritic cell149. This activity is conditioned by the retinoic acid (RA - a metabolite 
of vitamin A). Our current experiments in bone marrow derived DCs indicate that 
bacterial LPS downregulated adiponectin and its receptors. The conjugated 
effects of PPARγ agonists and retinoic acid reversed this state of adiponectin 
resistance. Moreover, this recovery was accompanied by a marked induction of 
IL10 expression. Our data is in agreement with the observation that PPARγ 
agonists induce adiponectin receptor expression in macrophages109. Additionally, 
it may further explain the protective effect of PPARγ activation in IBD colitis 35,110.  
Endoplasmic reticulum (ER) stress response may contribute to epithelial 
damage during DSS-induced colitis as well as in patients with IBD150. IL10 
mediated p38 mitogen-activated protein kinase (p38MAPK) signaling can block 
activation of the ER stress sensor – endoplasmic reticulum-binding protein (BIP) 
- after exposing intestinal cells to TNFα 83. Adiponectin can induce IL10 and 
activate p38MAPK 151-152. We now show that adiponectin treatment decreased 
ER stress response. Furthermore, it downregulated the expression of caspase-
12 (CASP12) which plays a central role in ER stress induced apoptosis 153. 
Epithelial cyclooxygenase 2 (COX-2) is induced during episodes of inflammation 
and mediates toll-like receptor 4 (TLR4) dependent mucosal repair 128,154. COX-
2-/- mice are more susceptible to DSS-induced colitis due to their inability to 
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produce prostaglandin E2 (PGE2)155. The finding of enhanced COX-2 production 
in mice overexpressing adiponectin and reduced ER stress markers points 
toward a significant protective effect of adiponectin in gut mucosa during 
inflammatory situations.  
In summary, we provide evidence that adiponectin and its plant homolog – 
osmotin - have an anti-inflammatory role in an established model of experimental 
colitis. In addition to altering the cytokine milieu, adiponectin may operate in 
complex regulatory networks that involve downregulation of pro-inflammatory 
adipokines angiotensin and osteopontin. Furthermore, adiponectin modulates the 
expression of epithelial protective factors, cellular stress response and immune 
cell traffic. In situations where adiponectin secretion is deficient, Osmotin, a plant 
derived adiponectin homologue or PPARγ agonists may restore its protective 
effects. Importantly, novel therapeutic strategies could be developed in order to 
mimic or enhance the anti-inflammatory action of adiponectin.  
 
Figure Legends 
                            
Figure 3.1.  The severity of DSS-induced colitis is decreased in mice receiving 
Adiponectin adenovirus. Mice were randomly assigned to three i.v. treatment 
groups: Control (Ctr) and the V+DSS groups received adenovirus reporter gene 
while the AN+DSS group received adenovirus adiponectin gene. The Ctr group 
was placed on water for 10 days. The V+DSS and AN+DSS groups were 
administered 3.5% DSS in drinking water for 7 days followed by 3 days of water.  
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(A) Body weight change between the last and first day of the experiment. (B) 
Hematocrit and (C) colon length at the end of the experiment.  Data are 
expressed as mean ± SE, n=6/group. Left panels: Immunohistochemistry for 
epithelial cell proliferative index (PCNA) of the colonic tissue of Ctr (upper panel), 
V+DSS (middle panel), and AN+DSS (lower panel).  
Figure 3.2. Efficacy of adenoviral delivery. Colonic adiponectin was increased at 
mRNA (A) and protein level (C) and correlated with plasma level (B) in mice that 
received adiponectin adenovirus (AN+DSS). 
 
Figure 3. 3. Expression of pro-inflammatory cytokines during DSS-induced colitis 
was decreased in mice overexpressing adiponectin (AN+DSS). Colonic (A) 
TNFα, (B) IL1β, (C) MCP1, (D) CCR2 gene expression. Data are expressed as 
mean ± SE, n=6/group  
Figure 3.4. Adiponectin treatment promoted an anti-inflammatory milieu during 
DSS administration. Increased IL10 colonic mRNA (A) and corresponding (B) 
plasma level in mice overexpressing adiponectin (AN+DSS). (C) Increased 
alternative macrophage (M2) marker - arginase 1- and (D) epithelial secretory 
leukoprotease inhibitor, consistent with limited tissue destruction in mice 
overexpressing adiponectin (AN+DSS). Data are expressed as mean ± SE, 
n=6/group  
Figure 3.5. Adiponectin treatment reduces the pro-inflammatory adipokines 
during DSS induced colitis. Angiotensinogen, the only known precursor of the 
pro-inflammatory angiotensin II was decreased (A) in AN+DSS group. (B) 
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Adiponectin overexpression downregulated the angiotensin II receptor 1 and the 
enzyme responsible for its generation (C) ACE. Adiponectin treatment reduced 
the colonic expression of the pro-inflammatory adipokine - osteopontin (D). Data 
are expressed as mean ± SE, n=6/group  
Figure 3.6. Adiponectin reduced cellular stress and apoptosis during DSS 
induced colitis. (A ) Decreased mRNA gene expression of endoplasmic reticulum 
stress response marker – BIP – and related pro-apoptotic factors – CHOP and 
Casp12 (B, C) during DSS colitis in mice overexpressing adiponectin (AN+DSS). 
Colonic COX-2 exerts proliferative and anti-apoptotic effects. High levels of 
adiponectin in AN+ DSS mice correlated with increased colonic COX-2 mRNA 
gene expression (D) and protein level (E). Data are expressed as mean ± SE, 
n=6/group  
Figure 3. 7. Osmotin - a plant derived adiponectin homolog - is beneficial in DSS 
colitis model. Saline (for the Ctr and DSS groups) or Osmotin (for the Osm+DSS 
group) were delivered as a 2 weeks infusion that overlapped the 10 days of 3.5% 
DSS colitis protocol. (A) Change in body weight between last and first day of 
DSS protocol. (B) Hematocrit at the end of the experiment. Osmotin treatment 
(Osm+DSS group) prevented weight loss and hematochezia during colitis. (C, D) 
Increased colonic and plasma level of the anti-inflammatory cytokine IL10 during 
DSS colitis in mice receiving Osmotin (Osm+DSS). Data are expressed as mean 
± SE, n=8/group  
Figure 3.8 PPARγ agonist and retinoic acid reversed the LPS induced 
adiponectin resistance in dendritic cells. Murine, bone marrow derived dendritic 
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cells were activated with LPS in the presence or absence of PPARγ agonist (R = 
rosiglitazone) and retinoic acid (RA -9-cis-retinoic acid). LPS did not affect 
dendritic cells’ adiponectin expression while rosiglitazone induced it (A). In the 
presence of LPS, both adiponectin receptors were downregulated (B, C).  
Rosiglitazone and retinoic acid acted synergistically to restore adiponectin 
receptors expression (B, C) and concurrently increased IL10 gene expression 
(D). Data are expressed as mean ± SE, n=3 replicates/treatment group.  
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Figure 3.1 The severity of DSS-induced colitis is decreased in mice receiving 
Adiponectin adenovirus 
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Figure 3.2 Efficacy of adenoviral delivery 
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Figure 3.3 Expression of pro-inflammatory cytokines during DSS-induced colitis 
was decreased in mice overexpressing adiponectin (AN+DSS) 
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Figure 3.4 Adiponectin treatment promoted an anti-inflammatory milieu during 
DSS administration 
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Figure 3.5 Adiponectin treatment reduces the pro-inflammatory adipokines during 
DSS induced colitis 
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Figure 3.6 Adiponectin reduced cellular stress and apoptosis during DSS induced 
colitis 
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Figure 3.7 Osmotin - a plant derived adiponectin homolog - is beneficial in DSS 
colitis model 
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Figure 3.8 PPARγ agonist and retinoic acid reversed the LPS induced 
adiponectin resistance in dendritic cells 
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Chapter Four 
The content of Chapter 4 has been published in the Journal of Inflammatory 
Bowel Disease. Permission to reproduce this material has been obtained from 
John Wiley & Son publishing company. 
 
ROLE OF THE XENOBIOTIC RECEPTOR IN INFLAMMATORY BOWEL 
DISEASE 
         Synopsis 
Background: Gene-environment interplay modulates Inflammatory Bowel 
Diseases (IBD). Dioxin-like compounds can activate the Aryl Hydrocarbon 
Receptor (AhR) and alter macrophage function as well as T cell polarization. We 
hypothesized that attenuation of the AhR signaling pathway will ameliorate colitis 
in a murine model of IBD.  
Design: DSS colitis was induced in C57BL/6 AhR null mice (AhR –/–), 
heterozygous mice (AhR – /+), and their wild type (WT) littermates. Clinical and 
morphopathological parameters were used to compare the groups. Patients: AhR 
pathway activation was analyzed in biopsy specimens from 25 IBD patients and 
15 healthy controls. 
Results: AhR –/– mice died before the end of the treatment. However, AhR – /+ 
mice exhibited decreased disease activity compared to WT mice. The AhR – /+ 
mice expressed less proinflammatory cytokines such as TNFα (6.1 versus 15.7 
fold increase) and IL17 (23.7 versus 67.9 fold increase) and increased anti-
inflammatory IL-10 (2.3 fold increase) compared with the AhR+/+ mice in the 
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colon. Colonic macrophage infiltration was attenuated in the AhR – /+ group.  AhR 
and its downstream targets were significantly upregulated in IBD patients versus 
control (CYP1A1 – 19.9, and IL8- 10 fold increase). 
Conclusion: Attenuation of the AhR receptor expression resulted in a protective 
effect during DSS-induced colitis, while the absence of AhR exacerbated the 
disease. Abnormal AhR pathway activation in the intestinal mucosa of IBD 
patients may promote chronic inflammation. Modulation of AhR signaling 
pathway via the diet, cessation of smoking or administration of AhR antagonists 
could be viable strategies for the treatment of IBD. 
 
Introduction 
Inflammatory Bowel Disease (IBD) is characterized by an inappropriate immune 
response to commensal flora. 156-157 In Western countries, 1 in 200 patients are 
affected by Ulcerative Colitis (UC) or Crohn’s Disease (CD), the major forms of 
IBD and their incidence is steadily increasing. 158  The causes of IBD are 
unknown and the diagnosis is based on clinical, endoscopic, radiological and 
histological criteria. 159 Differences between familial and geographic clustering 
point toward environmental factors. In Caucasians, smoking has the strongest 
association with the severity of the gut inflammation. 160-161   
Aryl Hydrocarbon receptor (AhR) is the only known receptor for dioxin, a 
potent immunomodulating environmental contaminant. Studies showed that 
cigarette smoke contains dioxins and dioxin-like chemicals. 162-164 The unbound 
AhR is present in the cytoplasm of all immune system cells. Furthermore, many 
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genes involved in immune regulation possess multiple dioxin response elements 
(DREs) in their promoter region. 94,165 Studies performed in AhR –/– mice have 
shown an enhanced inflammatory response to cigarette smoke or endotoxin, with 
elevated levels of tumor necrosis factor-α (TNFα) and interleukin-6 (IL-6). 166-167 
AhR is essential in the regulation of cell cycle , lipid metabolism 168 circadian 
rhythm 169 and immune response. 170  Although AhR seems to be a crucial co-
factor in regulation of both homeostasis and inflammation, its role in the gut 
autoimmune pathology is poorly described.  Surprisingly, sustained activation of 
AhR by its high affinity, prototypical agonist, 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin 
(TCDD), resulted in altered bone marrow and thymic development, as well as 
susceptibility to infectious diseases and cancer in mice. 171-172 Collectively, these 
observations suggest that a low to normal activation of AhR is beneficial for the 
protection against environmental insults, and represents an important link 
between environment and chronic diseases. 
      Our preliminary experiments indicated that AhR –/– mice are highly 
sensitive to DSS-induced colitis. In the current study, we examined the outcome 
of DSS-induced colitis in wild type and AhR heterozygous mice. Interestingly, 
moderation of the AhR signaling pathway in the AhR heterozygous mice was 
sufficient to ameliorate colitis. We also provide evidence that the level of AhR 
expression correlates with the profile of cytokines, adipokines and cellular stress 
response. These data indicate that attenuation of the AhR signaling pathway 
corresponds to an attenuated inflammatory response in the colon in disease-free 
conditions and during experimentally induced colitis. Furthermore, we extended 
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our observations in IBD patients were AhR pathway was significantly upregulated 
when compared to healthy controls. 
 
Materials and Methods 
Subjects and sample collection 
Colonic biopsies were obtained from 15 healthy controls and 25 IBD (Crohn’s 
Disease) patients. Control subjects were healthy individuals who underwent 
screening colonoscopy and had no inflammatory bowel conditions. IBD patients 
had an established diagnosis, based on standard endoscopic, radiologic, and 
histologic criteria. Informed consent was obtained before participation and the 
study protocol was approved by the Institutional Review Board of the University 
of Kentucky. 
 To examine the AhR activation in the lower digestive tract, biopsies were 
taken from the colon during standard colonoscopy. Two biopsies from each 
subject were fixed in formalin or RNA Later until analysis. The formalin fixed 
subset of biopsies was subject to standard histological staining and fluorescent 
immunohistochemistry. The RNA later subset of biopsies was used to assess the 
total mRNA using MagnaPure Compact RNA Isolation Kit (Roche).  cDNA was 
obtained using Transcription High Fidelity cDNA Synthesis Kit (Roche). Specific 
mRNA levels were quantified by real time reverse transcription-polymerase chain 
reaction (RT-PCR), using the IQ iCycler (Bio-Rad), and SYBR Green qPCR 
Supermix (Bio-Rad). Primers were obtained from SABiosciences, Frederick, MD. 
The mRNA levels for test genes were normalized to reference gene according to 
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the comparative CT method also referred to as the 2 ─ ∆∆CT method.  The formula 
used:  (2─ (CT test – CT reference)) x 100%.  
 
Animal treatments and sample collection 
Male, 3 months old C57BL/6 and AhR –/– mice (Jackson Laboratory), or AhR – /+ 
mice bred in-house to C57BL/6 mice (n = 10 mice/group) were housed in a 
pathogen-free environment with free access to food and water. Mice were 
administered 3.5% (wt/vol) DSS (ICN Biochemical) in water for a week, followed 
by 3 days of water only. Body weight, stool consistency and rectal bleeding were 
monitored daily.  On day ten, mice were euthanized with ketamine/xylazine 
(100/10 mg/kg ip) for blood and tissue harvest. The colons were removed and 
perfused with phosphate-buffered saline (PBS - pH 7.4), and measured. Half of 
each colon was fixed in RNAlater (Qiagen), and stored at -20°C. The other half 
was made in a “swiss roll”, cut and fixed in 10% buffered formalin (Sigma 
Chemical). The Animal Care and Use Committee at the University of Kentucky 
approved all procedures.  
 
Analysis of mRNA gene expression levels in mouse colonic tissue  
On day 10, total RNA was purified using MagnaPure Compact RNA Isolation Kit 
(Roche) from whole colon tissue and cDNA was obtained using Transcription 
High Fidelity cDNA Synthesis Kit (Roche). Specific mRNA levels were quantified 
by real time reverse transcription-polymerase chain reaction (RT-PCR), using the 
IQ iCycler (Bio-Rad), and SYBR Green qPCR Supermix (Bio-Rad). Primers were 
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designed using the Primer 3 software (SourceForge) and the sequences are 
shown in Table 1 (supplemental material).  
The mRNA levels for test genes were normalized to reference gene according to 
the comparative CT method also referred to as the 2 ─ ∆∆CT method.  The formula 
used:  (2─ (CT test – CT reference)) x 100%.  
 
Measurement of cytokines in the colonic tissue 
At day 10, we measured cytokines in the colonic tissue homogenate using a 
bead based immunoassay (Lincoplex) multianalyte detection platform (Luminex - 
Mouse Cytokine Panel). Values are expressed in picograms per milliliter and as 
mean ± SE, n=10 / group. 
 
Histology 
Serial sections (5 -7 μm) of paraffin embedded colons (swiss roles) were stained 
with hematoxylin and eosin.  A pathologist blinded to the group allocation 
assessed the severity of colitis. The scoring system evaluated the following 
characteristics: (1) percentage of area involved, (2) number of follicle aggregates, 
(3) edema, (4) erosion/ulceration, (5) crypt loss, and (6) infiltration of 
mononuclear and polymorphonuclear cells. The total score ranges from 0 to 26. 
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Proliferating Cell Nuclear Antigen (PCNA) assay 
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The sections were deparaffinized and treated with Antigen Retrieval Solution 
(DAKO, Carpinteria, CA) followed by incubation in 0.3% H2O2-methanol for 10 
min, and wash. Sections were incubated in normal blocking serum for 90 min 
followed by overnight incubation in primary antibody, NCL-PCNA (1:200) 
(Novocastra, Leica Microsystems) at 4°C. The biotinilated secondary antibody 
(Elite ABC kit, Vector) was then applied for 2 hours. The slides were 
counterstained with Methyl Green (DAKO). Images were taken with an Olympus 
BX51 microscope (Olympus America Inc.). 
 
Fluorescent Immunohistochemistry  
Formalin-fixed, paraffin embedded colon sections (5-7 μm) placed on coated 
slides were sequentially deparaffinized and rehydrated using xylene and ethanol. 
Slides were then treated for 10 min with a citric acid-based antigen-unmasking 
solution (Vector Laboratories, Burlingame, CA). Next, slides were incubated for 1 
hour at room temperature in normal blocking serum (1% in PBS) and incubated 
overnight at 4°C with the respective primary antibody (dilution 1:50): Angiotensin 
II (BGN/0856/21) - a mouse anti-human monoclonal antibody, AT1 (306: sc-579) 
- a rabbit anti-human polyclonal antibody or ACE (H-170: sc-20791) - a rabbit 
anti-human polyclonal antibody, (Santa Cruz Biotechnology, INC, CA). On the 
second day, after washing, sections were incubated for 1 h with a mixture of Cy2-
conjugated goat anti-mouse IgG and Cy3-conjugated goat anti-rabbit IgG 
(Jackson ImmunoResearch Laboratories, West Grove, PA, catalog numbers 115-
225-146 and 111-165-144). Sections were counterstained with 4’, 6-diamidino-2-
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phenylindole dihydrochloride (DAPI) (Molecular Probes Invitrogen, Eugene, OR) 
to visualize nuclei, and mounted with VECTASHIELD® medium (Vector 
Laboratories, Burlingame, CA). Images were taken with an Olympus BX51 
microscope, using a 20x objective. We generated the composite images using 
Image-ProPlus 5.0 (Media Cybernetics, Inc.) software.  
 
Statistical analysis  
Data are expressed as Mean ± SE. Data were analyzed using unpaired t-test and 
one-way analysis of variance (ANOVA) (GraphPad Prism 5) followed by Tukey’s 
test with significance accepted at p < 0.05. Body weight data were analyzed by 
one-way ANOVA with repeated measures on time. Survival percentage has been 
calculated using Kaplan-Meier method. Significance was accepted at p < 0.05. 
 
Results 
The severity of DSS- induced colitis is decreased in AhR -/+ mice  
Preliminary experiments showed that AhR KO mice do not survive beyond day 7 
to DSS induced colitis (Figure 4.1A). Therefore, in the current study, AhR – /+ and 
WT mice were analyzed. There was circa 50% reduction in AhR mRNA 
expression in colonic tissue of  
AhR – /+ mice that was maintained during colitis (Figure 4.1B). Before DSS 
administration, there were no differences in body weight among groups. On day 
ten, WT mice lost significantly more weight (Figure 4.1C. p=0.001), had a 
significant drop in the hematocrit (Figure 4.1D, p=0.002), and the postmortem 
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exam revealed swollen and shortened colons compared to AhR – /+ mice exposed 
to DSS (Figure 4.1E, p=0.01). Microscopically, colitis was mild in the AhR – /+ 
group as compared with significant mucosal ulceration, crypt abscesses and 
altered architecture present in WT mice and reflected in the histology score 
(Figure 4.1F, p=0.001), and H&E stained colon sections (Figure 4.2A). 
Furthermore, Proliferating cell nuclear antigen (PCNA) staining revealed a 
significant decrease in crypt proliferative activity in WT group as compared to the 
AhR – /+ group (Figure 4.2B), consistent with defective epithelial turnover. 
Importantly, there were no significant differences between AhR – /+ with and 
without colitis and the control water fed WT mice. 
 
AhR -/+ genotype favors Th2 over Th1 type cytokine expression 
The cytokine milieu within the gut defines the outcome of both innate and 
acquired immune cells activation. We investigated the expression of classical 
Th1/Th2 cytokines previously documented in mice with DSS induced colitis and 
IBD patients (27). Wild type mice exposed to DSS developed colitis that was 
characterized by increased expression of TNFα gene and protein level (Figure 
4.3A, 3B, p=0.001). Importantly, AhR – /+  mice had significantly lower baseline 
TNFα gene (Figure 4.3A )  and protein level ( Figure  4.3B)  expression as 
compared to that in wild type mice and did not change during colitis. Intestinal 
macrophages play a central role in the immune response to commensal flora and 
become a source of Th1 cytokines in IBD. (28) The mRNA gene expression of 
the macrophage marker F4/80 (Figure 4.3C, p=0.018) was downregulated in AhR 
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– /+ mice treated with water or DSS. The immunostaining of gut sections from AhR 
– /+ mice with colitis showed a significant decrease in macrophage infiltration 
(Macrophage-restricted protein-F4/80 - green, Figure 4.7), consistent with a 
dampened innate immune response as compared with WT mice with colitis. 
Although the monocyte chemoattractant protein (MCP1) expression increased 
during colitis in AhR – /+ mice, this was significantly lower compared to wild type 
mice (Figure 4.3D, p=0.005). Baseline expression of IL10 within the colon was 
similar in control AhR – /+ and WT mice. Nevertheless, during DSS colitis there was 
significant upregulation of this anti - inflammatory cytokine only in AhR – /+ mice 
(Figure 4.3E, 4.3F, p=0.005). In addition, we observed a more prominent 
induction of anti-inflammatory Secretory leukocyte protease inhibitor (SLPi) in 
AhR – /+ mice (suppl. Fig 10, p=0.0001) as compared to that in the WT mice 
during DSS induced colitis. SLPI is mainly expressed in the colon by the 
epithelial cells and is a potent inhibitor of Th1 like cytokines. 174 
Th17 to Treg shift occurs during DSS-induced colitis in AhR -/+ mice 
Aside from the classical Th1/Th2 paradigm, we further investigated the 
expression of master regulators for Th17 and Treg cells during colitis. Under 
basal conditions there were no differences between the AhR – /+ mice and WT 
(Figure 4.4A-D). During DSS colitis there was a significant up regulation of Treg 
specific transcription factor FOXp3 gene expression in AhR – /+ mice as 
compared to that in the WT mice (Figure 4.4A, p=0.004). In contrast, the mRNA 
expression of Th17 specific transcription factor, RORγ was significantly 
downregulated in AhR – /+ mice relative to the WT mice (Figure 4.4B, p=0.021). 
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Consistent with the latter finding we observed a significant attenuation of IL17 
gene expression and protein level in AhR – /+ mice (Figure 4.4C-D). 
 
Pro-inflammatory adipokines are decreased in AhR -/+ mice during DSS colitis 
Mesenteric adipose tissue can become a source of inflammatory adipokines like 
angiotensin and osteopontin. Thus, during postmortem collection of the colons, 
we carefully removed the adjacent fat tissue. Nevertheless, these mediators can 
also be expressed in gut epithelia and lamina propria immune cells. (29-31)  We 
confirmed that both AhR – /+ and WT C57BL/6 mice express components of the 
angiotensin system (Figure 4.5 A-E) as well as osteopontin ( Figure 4.5 D) within 
the colon. Pharmacological blockade of renin-angiotensin system has been 
shown to decrease the severity of colitis in several mouse models. (30, 32)  We 
show that AhR – /+ mice treated with DSS presented a significant downregulation 
of the only known precursor of angiotensin I/II - angiotensinogen (Figure 4.5A, 
p=0.0001), as well as the angiotensin converting enzyme ACE (Figure 4. 5B, 
p=0.0048), and angiotensin receptor AT1 (Figure 4.5C, p=0.003) gene 
expression compared to the WT group. Importantly, the AhR – /+ mice presented 
significant less AT1 mRNA gene expression under basal conditions (Figure 4.5C, 
p=0.023). Compared to WT mice with colitis, the immunohistochemistry of colon 
sections of AhR – /+ mice with colitis revealed decreased angiotensin II, AT1 
receptor (Figure 4.5E) and ACE expression (suppl. Figure 4.11).  
 
Adiponectin, the anti-inflammatory adipokine is increased in AhR -/+ mice during  
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DSS induced colitis 
Adiponectin, the only known anti-inflammatory adipokine, is considered an 
exclusive product of adipose tissue. Here, we show that adiponectin gene is also 
expressed in the colon (Figure 4.6A).  Next, we asked whether induction of colitis 
impairs adiponectin expression, and/or promotes a state of adiponectin 
resistance by down regulating its receptors. All the AhR – /+ mice presented a 
higher basal adiponectin mRNA gene expression that did not change during 
treatment. Importantly, adiponectin mRNA gene expression dropped significantly 
in the wild type mice during colitis (Figure 4.6A, p=0.0006). Consequently, 
adiponectin receptors (AdipoQ R1 and R2) were downregulated during DSS 
colitis in all groups (Figure 4.6 C, D). Interestingly, T-Cadherin mRNA gene 
expression, a novel adiponectin receptor that serves to anchor adiponectin to cell 
surface 175, was upregulated only in the AhR – /+ mice and not in the WT mice 
with colitis (Figure 4.5B, p=0.037). Moreover, AhR – /+ mice exposed to DSS had 
a lower expression of Protein of 44 kDa (Erp44) that inhibits the secretion of 
adiponectin oligomers from the endoplasmic reticulum (ER).  In addition, the ER 
oxidoreductase 1-Lα (Ero1-Lα), an ER chaperone that releases adiponectin 
trapped by Erp44 had similar expression in all groups. (Figure 4.6D-E, p=0.002). 
Therefore, by modulating the ratio of these ER chaperones the attenuated AhR 
signaling pathway favors the secretion of the anti-inflammatory adiponectin 
during experimentally induced colitis. 
. 
The AhR+/- mice with DSS induced colitis have less endoplasmic reticulum (ER) 
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stress response. 
The development of colitis during DSS administration is associated with high 
cellular stress due to accumulation of misfolded proteins within the colonic 
epithelium. ER binding protein (BIP/ Grp78) acts as an intracellular sensor and is 
considered a marker of ER stress 176. X-Box Binding Protein 1 (XBP1) is a 
transcription factor induced by ER stress that exerts a protective role and thus 
allows cells to recover. 177 In our study we observed a significant downregulation 
of ER stress markers BIP (p=0.018) and XBP1 (p=0.002) in the AhR – /+ mice 
exposed to DSS as compared to the WT mice with colitis (Suppl. Figure 9). Since 
ER stress response is coupled to the cell death program, we investigated the 
mRNA expression of two pro-apoptotic molecules: C/EBP Homologous Protein 
(CHOP) and Caspase 12 (Casp12). There was a significant downregulation of 
the expression of both pro-apoptotic genes only in the AhR – /+ mice exposed to 
DSS (Suppl. Figure 4. 9). 
 
AhR pathway is activated in patients with Inflammatory Bowe Diseases. 
In this study we have shown that AhR pathway can modulate the inflammatory 
response during experimental colitis. Then, using immunohistochemistry we 
investigated the pattern of AhR expression in healthy controls and patients with 
Crohn’s Disease. In human subjects without IBD, AhR expression was confined 
to the epithelial layer (Figure 4. 8C), whereas in Crohn’s Disease there was a 
significant influx of AhR+ cells in the lamina propria compartment (Figure 4.8D) 
corresponding to pro-inflammatory hematopoietic cells. AhR pathway activation 
109 
 
was assessed by measuring the expression of its downstream target, CYP1A1. 
There was negligible expression in healthy controls while a 19.9 fold upregulation 
was noted in IBD patients (Figure 4.8A). IL-8 is a chemokine, which promotes 
neutrophil recruitment in patients with IBD. Human IL-8 promoter contains 
xenobiotic responsive elements (XRE) and thus can be upregulated by AhR 
signaling. 178 Similar to the prototypical AhR target CYP1A1, IL-8 expression was 
upregulated 10 fold in patients with Crohn’s Disease (Figure 4. 8B). 
 
Discussion 
 
Although the precise pathogenesis of IBD still needs to be unraveled, 
recent studies have reinforced the strong association between smoking, disease 
severity, complications and resistance to treatment. 161,179  Mahid et al. found a 
greater prevalence of IBD patients in Kentucky, a state that ranks second in the 
nation in tobacco production and first in its use. 180  Mainstream cigarette smoke 
contains high level of dioxins and dioxin-like chemicals that are known to be 
strong inducers of AhR. 162-163  In addition to their prolonged half-life, these 
ubiquitous contaminants are highly lipophilic and accumulate in the adipose 
tissue181, possibly leading to a prolonged activation of the AhR signaling 
pathway. 182   
Persistent activation of the AhR has been extensively researched using 
TCDD, a high affinity AhR agonist. 183  Administration of TCDD to laboratory 
animals induces inflammation by promoting tissue migration of immune cells 184-
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185, and an increase in pro-inflammatory cytokine expression. 186-187 Surprisingly, 
macrophages isolated from mice lacking the AhR produce higher amounts of the 
inflammatory cytokines IL-1, IL-6 and TNFα in response to LPS. 188-189 Earlier 
studies indicated that AhR null mice develop colitis and rectal prolapse and have 
a propensity to develop colon cancer. 190  The inferred conclusion from the data 
obtained from  either  the ligand-activated  AhR cell lineages or AhR null mice 
clearly states the physiological importance of this receptor in cell growth 191-192, 
cell apoptosis 193, elaborate cross-talk with NF-kB 194-195, and ER stress 
response. 196  
To explore the association between the AhR pathway and IBD 
pathogenesis, we induced colitis in AhR - /-, AhR – /+, and AhR + /+   mice. We 
found that mice lacking the AhR succumbed early to inflammation while the WT 
developed severe colitis. In comparison, the AhR heterozygous mice had a good 
clinical outcome during DSS administration and presented little structural 
changes in intestinal mucosa architecture.  
Macrophages play an important role in the innate immune response to 
bacteria. In patients with Crohn’s disease, there is an influx of CD14+ 
macrophages within the gut, which become a rich source of TNFα. 197 Blockade 
of this proinflammatory cytokine induces disease remission in patients with IBD 
and in experimental models of colitis. 198-199  We found that AhR – /+ mice express 
significantly lower levels of TNFα as compared to that observed in the WT groups 
under both, disease-free conditions and during experimentally induced colitis. 
Moreover, the expression of the Macrophage-restricted protein F4/80 was 
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decreased in the colon of AhR – /+ mice during colitis.  It is increasingly 
acknowledged that the AhR pathway modulates a number of immune 
responses.200  While the specific AhR-induced mechanisms that underlie its 
effects on the immune system are poorly understood, numerous genes activated 
during the immune response have been found to contain DNA recognition sites 
for the AhR/ARNT heterodimers. (47, 48)   Furthermore, the AhR pathway has 
been shown to play a significant role in the development of both Th17, and Treg 
cells. 95 The pathogenic role of Th17 cells as well as defective function of T-
regulatory cells has been found in patients with Crohn’s disease and animal 
models of IBD. 201-202 In the current study, we show that there is significant 
downregulation of the Th17 lineage master regulator, RORγ, with a 
corresponding upregulation of Treg transcription factor Foxp3 in the colon of  AhR 
– /+ mice during colitis. Consistent with these changes, we have also noted a 
significant decrease in the IL-17 expression and a corresponding increase in IL-
10 expression. Thus, the attenuation of the AhR signaling pathway correlates 
with the outcome of experimental colitis and the Th17 / Treg balance in the colon.  
The adipokines and cytokines secreted by adipose tissue have been 
increasingly recognized as bona-fide immune regulators. Angiotensin, a 
proinflammatory adipokine is generated from angiotensinogen through the 
proteolytic activity of ACE and tissue chymases. AT1a is the main receptor that 
mediates the pro-inflammatory actions of angiotensin. 203 Intestinal mucosa is a 
rich source of ACE, while macrophages express the full renin-angiotensin 
system. Increased ACE was reported in Crohn’s disease patients, while Ace/AT1 
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blockade protects mice from experimental colitis. 77,204 In our study, AhR wild 
type mice that developed colitis had high expression of the angiotensin system 
components. Furthermore, there was a significant increase in lamina propria cells 
expressing both angiotensin and AT1a. We have previously shown that AhR 
agonists induce expression of angiotensinogen and proinflammatory cytokines in 
cultured adipocytes. 181 Our current finding that  AhR – /+ mice fail to upregulate 
angiotensin system during DSS colitis further implicate this system in AhR- 
mediated inflammation.  
Adiponectin, the primary adipokine with anti-inflammatory activity was 
downregulated in the wild type AhR mice that developed severe colitis, while the 
opposite was found in AhR – /+ group. We have previously demonstrated that AhR 
activation downregulates the expression of this adipokine in fat cells. 181  In the 
current study, we report that attenuated AhR expression/activity in the AhR – /+ 
mice, correlates with increased colonic adiponectin and its T-Cadherin receptor 
expression during DSS treatment.  Moreover, our study indicates that AhR 
modulates the expression of ER chaperone proteins that regulate adiponectin 
secretion. These correlations might be very important since adiponectin has a 
protective role in experimental colitis as recently shown by the Nishihara group. 
42 Furthermore, it was demonstrated that adiponectin treatment protects 
adiponectin KO mice from developing DSS-induced colitis. In addition, 
adiponectin has been shown to induce IL-10205, and thus, promote alternative 
activation of macrophages and resolution of chronic inflammation. In our study, 
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the increased adiponectin in AhR – /+ mice may have had an important role in 
maintaining tissue homeostasis during DSS induced colitis.  
Recent studies have shown that an increased endoplasmic reticulum 
stress response in epithelial cells promotes colitis. Importantly, mutations in 
XBP1, a key component of this response, have been associated with Crohn’s 
disease. 126  In the current study, DSS-induced colitis resulted in an increase 
expression of ER stress markers in wild-type mice, while they were 
downregulated in the AhR – /+ mice. Furthermore, increased IL-10 expression in 
the latter group may have also reduced the stress response associated with 
colitis. 206  It is also possible that the ER stress response during colitis facilitates 
AhR signaling and their reciprocal induction leads to the inflammatory response 
associated with DSS induced colitis. 207  
The effect of AhR activation on T cells is ligand dependent. TCDD induces 
persistent activation of AhR in Treg cells. 94 On the other hand dietary derived, 
short acting ligands, such as FICZ (6-formylindolo, 3, 2-b-carbazole) induce Th17 
differentiation. 208 The relative abundance of the different ligands, along with the 
AhR system polymorphisms may further modulate the response. 93,209 In our DSS 
model, AhR activation most likely occurred through dietary (i.e. FICZ) and 
endogenous ligands with similar kinetics, thus explaining the upregulation of IL-
17 and RORγ. The increased expression of colonic macrophages in wild type 
mice compared to AhR – /+ further supports the role of this receptor in colitis. 
Recent in-vitro studies in macrophages described an ARNT independent, non-
genomic pathway downstream of AhR that induces an inflammatory response. 210 
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We hypothesize that low AhR expression may be coupled to the classical signal 
that downregulates macrophage function whereas increased receptor expression 
preferentially activate the non-genomic pathway and hence promotes 
inflammation.  
Our studies in patients without IBD indicate that AhR is mainly expressed 
in the epithelial layer. Nevertheless, this translated in minimal activation of this 
pathway and likely fulfills a physiologic role such as cell cycle regulation and 
metabolism of diet derived xenobiotics. AhR is important for the development of 
Th17 cells and can upregulate human macrophage expression of IL-8.178 These 
activities are highly relevant for the ongoing intestinal inflammation of IBD 
patients. The robust AhR activation shown in our Crohn’s Disease patients was 
secondary to the influx of lamina propria AhR+ mononuclear cells, like macrophages 
and T cells. Consistent with this observation, we found high IL-8 expression that 
mirrored the AhR classical target, CYP1A1. 
In summary, we provide novel evidence that dysregulated expression of 
the AhR alters the outcome of colitis. The extreme phenotypes of AhR null and 
wild types groups indicate that AhR pathway fulfills both tissue homeostatic and 
inflammatory roles. Furthermore, we show that AhR pathway activation 
distinguishes Crohn’s Disease patients from healthy controls. Modulation of this 
pathway through diet, cigarette smoking cessation, as well as pharmacological 
antagonism of the AhR could be viable strategies for the treatment of IBD. 
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Figure Legends 
Figure 4.1. The severity of DSS-induced colitis is attenuated in AhR – /+ mice. 
Mice were administered 3.5% DSS dissolved in water for 7 days followed by 3 
days of water. Control mice received water alone for 10 days. (A) Kaplan-Meier 
plot showing premature lethality of male AhR– /–  when compared with WT and 
AhR – /+  littermates (B) AhR mRNA gene expression in the colonic tissue (C) 
Body weight (D) Hematocrit (E) Colon length (F) Histopathological grading of 
colonic inflammation at the end of the experiment. Data are expressed as mean 
± SE, n=10/group.  
Figure 4.2. Decreased histological severity in AhR – /+ mice during DSS-induced 
colitis.  (A) H&E-staining of colons from WT (upper panel) and AhR– /+ mice (lower 
panel). (B) Immunohistochemistry for epithelial cell proliferative index (PCNA) in 
sections of the colonic tissue of WT (upper panel) and AhR– /+ mice (lower panel). 
Figure 4. 3. The expression of pro-inflammatory cytokines and macrophage 
marker are reduced in AhR – /+ mice during colitis. (A) TNFα gene expression, (B) 
TNFα protein level, (C) F4/80 gene expression (D) MCP1 gene expression, (E) 
IL10 gene expression and (F) IL10 protein level in colonic tissue. Data are 
expressed as mean ± SE, n=10 / group       
Figure 4. 4. Differential expression of master regulators for Treg and Th17 cells 
in the colon of WT and AhR – /+ mice.  Increased expression of (A) FoxP3 mRNA 
gene expression and attenuated gene expression of (B) RORγ and (C) IL17 with 
a low level of (D) IL17 protein expression in AhR – /+ mice treated with DSS. Data 
are expressed as mean ± SE, n=10/group.  
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Figure 4.5. Proinflammatory adipokines are decreased in AhR – /+ mice treated 
with DSS. The pro-inflammatory adipokines (A) Angiotensinogen (B) ACE, (C) 
AT1a receptor, (D) Osteopontin gene expression were significantly lower in AhR 
heterozygous mice during colitis. Data are expressed as mean ± SE, n=10/group. 
(E) Fluorescence immunohistochemistry for angiotensin II (green) and AT1aR 
(red) in AhR – /+ and WT mice treated with DSS. (a), (b) show dual staining 
Figure 4.6. Adiponectin is negatively regulated during colitis only in WT mice and 
not in the AhR – /+ mice. (A) Adiponectin gene expression in WT mice treated with 
DSS was significantly lower compared to AhR – /+ mice. (B) Decreased T- 
Cadherin receptor expression in WT mice with colitis. (C) and (D) Decreased 
adiponectin receptors in the context of low adiponectin expression may further 
impair this adipokine signaling pathway. (E) Increased gene expression of 
chaperone protein ERP44 relative to its partner, endoplasmic reticulum 
oxidoreductin (ERO) can block the secretion of adiponectin in WT mice with 
colitis. Data are expressed as mean ± SE, n=10/group.  
Figure 4.7. Reduced macrophage recruitment during DSS colitis in the AhR – /+ 
mice. Fluorescent immunohistochemistry showing macrophage-restricted protein 
- F4/80 expression in colonic tissue of AhR-/+ mice with colitis. (A) Macrophage-
restricted protein-F4/80 (green) in control groups, (B) Macrophage-restricted 
protein-F4/80 (green) in DSS-treated mice groups.  
Figure 4.8. AhR activation in patients with IBD. (A) CYP1A1 mRNA gene 
expression level is increased in IBD patients compared with control. (B) IL8 
mRNA gene expression increases during the inflammatory process in IBD 
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patients. Control n=15, IBD n=25.  Data are expressed as median. (C, D) 
Fluorescent Immunohistochemistry staining of the AhR in a control patient (C) 
versus a patient with Crohn’s disease (D). Representative images are shown of 
biopsies obtained from a control subject (C) and from a patient with Crohn’s 
disease (D). Red staining indicates binding of the antibody to human AhR. All 
samples were counterstained with DAPI (blue) to visualize nuclei. Magnification 
is 20X. E - Enterocytes and LP- Lamina Propria.  
Supplemental Figure 4. 9. Epithelial cellular stress is decreased in AhR – /+ mice 
exposed to DSS.  Decreased mRNA gene expression of endoplasmic reticulum 
stress response proteins (BIP, XBP1) and related pro-apoptotic factors (CHOP, 
Casp12).  Data are expressed as mean ± SE, n=10/ group  
Supplemental Figure 4.10. Decreased expression of Secretory leukoprotease 
inhibitor (SLPi) in WT compared to AhR – /+ mice exposed to DSS, consistent with 
reduced inflammation in the AhR heterozygote mice during colitis. mRNA gene 
expression in colonic tissue. Data are expressed as mean ± SE, n=10/group.  
Supplemental Figure 11. Decreased renin angiotensin system (RAS) 
components in AhR – /+ mice correlates with a better outcome of DSS-induced 
colitis in AhR heterozygote mice. Fluorescent immunohistochemistry shows 
expression of ACE (red – upper panels), Angiotensin (green – lower panels) and 
their co-localization (middle panels) in the colonic tissues of mice treated with 
water (left panels) compared with DSS treatment (right panels).   
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Figure 4.1 The severity of DSS-induced colitis is attenuated in AhR – /+ mice 
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Figure 4.2 Decreased histological severity in AhR – /+ mice during DSS-induced 
colitis 
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Figure 4.3 The expression of pro-inflammatory cytokines and macrophage 
marker are reduced in AhR – /+ mice during colitis 
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Figure 4.4 Differential expression of master regulators for Treg and Th17 cells in 
the colon of WT and AhR – /+ mice 
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Figure 4.5 Proinflammatory adipokines are decreased in AhR – /+ mice treated 
with DSS 
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Figure 4.6 Adiponectin is negatively regulated during colitis only in WT mice and 
not in the AhR – /+ mice 
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Figure 4.7 Reduced macrophage recruitment during DSS colitis in the AhR – /+ 
mice 
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Figure 4.8 AhR activation in patients with IBD 
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Supplemental Figure 4.9 Epithelial cellular stress is decreased in AhR – /+ mice 
exposed to DSS 
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Supplemental Figure 4.10 Decreased expression of Secretory leukoprotease 
inhibitor (SLPi) in WT compared to AhR – /+ mice exposed to DSS, consistent 
with reduced inflammation in the AhR heterozygote mice during colitis 
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Supplemental Figure 4.11 Decreased renin angiotensin system (RAS) 
components in AhR – /+ mice correlates with a better outcome of DSS-induced 
colitis in AhR heterozygote mice 
 
 
 
 
Copyright @ John Wiley & Son publishing company 
129 
 
Chapter 5.  
Conclusions: 
          Inflammatory Bowel Diseases are heterogeneous chronic relapsing 
conditions divided into two main phenotypes: Crohn's Disease and Ulcerative 
colitis. 1.Each category is further sub-typed according to established clinical 
criteria that take in consideration disease location, age at diagnosis and specific 
complications14. Nevertheless, this approach does not offer insight into the 
immune mechanisms that contribute to a unique phenotype. Moreover, it 
assumes that Inflammatory Bowel Diseases are a continuum development of a 
common pathologic process and expected to yield similar results to treatment.  
            Evidence from experimental models of Inflammatory Bowel Diseases is 
somewhat deceptive since knockouts of specific proinflammatory cytokines 
appear to cure the disease in spite of the clinical results in patients. A classic 
example is tumor necrosis factor alpha (TNFα). TNFα-KO mice are resistant to 
TNBS-hapten induced colitis and overexpression of a TNFα transgene results in 
severe colitis211. Clinical trials in IBD patients indicate that only 30% of patients 
on anti-TNF therapy achieve long-term remission212. We have investigated the 
mRNA expression of TNFα in mucosal biopsies from healthy volunteers and 
patients with Inflammatory Bowel Diseases213. In both groups, we noted a 
significant variation in expression and concluded that alone, this cytokine will not 
be informative. A similar trend was noted for other molecular targets relevant to 
the mucosal immune system. Genetic variations, unique microflora as well as 
redundant inflammatory pathways may explain the heterogeneity. On the other 
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hand, the concept of "physiologic gut inflammation" allows for cytokines such as 
TNFα to play both protective and pathologic roles, and its relative expression less 
significant.  Given the focused approach of current biologic therapies in IBD, it is 
important to determine the immune phenotype of these patients. Instead of 
pursuing isolated molecular targets, we investigated patterns of expression, for 
multiple factors, relevant to the innate immune function of the gut.  Principal 
component analysis of the relative expression of RelA, A20, pIgR, TNF, and IL-8 
in IBD (Crohn's type) allowed us to stratify patients into three immune 
phenotypes. Furthermore, they were correlated with treatment outcome and 
provided a "molecular signature" for Crohn's Disease. RelA, A20, pIgR, TNF 
mainly defined the first component of this statistical analysis (PC1), while the 
second one, (PC2) was weighted toward TNF, and IL-8. A high PC1 score and 
low PC2 characterized healthy volunteers and Crohn's Disease patients with very 
mild disease. This suggests that RelA, A20, and pIgR fulfill a protective role in 
the gut mucosa while TNFα and IL-8 are mainly pathogenic. Although NF-kB 
regulates the production of inflammatory cytokines, recent studies confirmed its 
importance for the integrity of epithelial barrier15 . Absence of ubiquitin-modifying 
enzyme A20 leads to excessive NF-kB stimulation downstream of TNFα and TLR 
signaling28. Thus, it provides a negative feedback, and likely contributes to the 
"physiologic inflammation". Another important intestinal epithelial NF-kB target is 
pIgR. Its baso-apical traffic ensures the continuous IgA transport in the gut lumen 
and thus contributes to the mucosal immune homeostasis214. The subgroup of 
patients with the lowest pIgR expression (lowest PC1) had almost absent IgA 
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transport. Interestingly the IgA was deposited in the lamina propria similar to 
patients with IgA nephropathy. They had higher than normal serum IgA as well. 
One explanation for the latter finding is that increased lamina propria IgA is taken 
up into the circulation. On the other hand, low pIgR expression may lower the 
epithelial defensive capacity and allow bacterial translocation, which in turn 
stimulates the IgA response to luminal bacteria. This conclusion is supported by 
evidence of barrier defects in pIgR knockout mice 23 as well as increased 
circulating antibodies to luminal bacteria in IBD patients215-216. Interestingly these 
patients had low NF-kB, TNFα and IL8 expression consistent with an immuno-
deficient status in the absence of immunomodulatory drugs. Clinically these 
patients were refractory to medical therapy. Since their previous treatment, 
regimens were largely immunosuppressive we can argue that this group would 
be candidate for immunostimulatory regimens such as GM-CSF. Our findings are 
in agreement with prior evidence of innate immune deficiency in Crohn's Disease 
patients217-218. Similar to our patients they had a blunted IL8 response.  The most 
common genetic mutation in CD patients involves NOD2 gene. Current studies 
link this intracellular bacterial sensor to protective NF-kB signaling in gut 
epithelium as well as mucosal defensin production by Paneth cells219. 
Nevertheless, we did not find an association with our patient subsets.  Crohn's 
Disease patients with high C reactive protein levels tend to be more responsive 
to anti-TNF therapy220. Our subset of patients with high PC2 scores (higher TNF, 
IL8) matched these characteristics. They tended to be earlier in the disease 
process as well. It should be noted that TNFα and IL8 expression was elevated in 
132 
 
areas unaffected by disease and were not simply markers of acute inflammation. 
The identification of signature biomarkers of Crohn's Disease has several 
implications: 1) subset 1(↑PC1↓PC2) may not require top-down therapy and/or 
do well with drug holidays; 2) subset 2 (↓PC1↓PC2) should be the object of 
immunostimulatory therapies and definitely avoid combinations of 
immmunosupressives; 3) subset 3 (↑PC2) can benefit early top-down, 
combination therapy. Future prospective studies will investigate whether early 
top-down therapy could switch subset 3 to subset 1 since the latter group is more 
likely to maintain remission in the absence of medical treatment. Furthermore, 
principal analysis of these signature biomarkers should be evaluated in various 
existing models of IBD and provide immune-phenotype specific insight for 
various potential treatments. In light of association between oral and intestinal 
inflammation, we are investigating the usefulness of oral sampling in lieu of the 
more invasive gut biopsies. 
           In light of our findings we propose that activation of downstream of extra 
and intracellular microbial sensors induces/activates NF-kB and its target genes 
pIgR, IL8 and TNFα. Activation of NF-kB is limited by A20 mediated inhibition 
and thus prevents ongoing inflammation. Increased pIgR expression assures 
adequate IgA transport with an important role in tolerance toward commensals 
and possibly neutralization of the proinflammatory chemokine IL8. The severe 
IBD phenotype observed in the subset of patient with low pIgR expression 
reflects an immune deficiency of the gut epithelium. These patients have low NF-
kB relA levels, which may theoretically be linked to ER stress response and 
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defective autophagy mechanisms. Ongoing anti-TNF treatment of these patients 
may aggravate the immune barrier dysfunction and favor a Th17 response to 
invading bacteria. 
          Crohn’s disease patients develop transmural inflammation of the 
gastrointestinal tract, which may lead to complications such as strictures and 
perforations. Often times, there is significant hypertrophy and inflammation within 
the surrounding mesenteric fat. Recent advances in metabolic and 
cardiovascular diseases have led to a paradigm shift in which adipose tissue has 
been upgraded from an energy depot to a source of immunomodulatory 
cytokines (adipokines). In his original description of the disease, Burril Crohn 
described the characteristic mesenteric fat change100. Although widely 
recognized, the relevance of this fat hypertrophy, referred to as “creeping fat”, is 
unknown, and has received little research attention.  Accumulation of mesenteric 
fat, appears to be specific for Crohn’s disease, and occurs from the onset of 
disease37. Fat wrapping has been defined as fat hypertrophy extending from the 
mesenteric attachment with > 50% coverage of the intestinal surface101. It occurs 
in both the small and large bowel, and correlates with transmural inflammation, 
ulceration, stricture formation, increased mesenteric wall thickness, and 
decreased internal bowel diameter101.  Fat wrapping and mural thickening is 
associated with mucosal ulceration in 86% of patients102 and with strictures in 
46%102.  Importantly it  was noted in 100% of patients undergoing resection, and 
correlated with the degree of acute and chronic inflammation103.  Adiponectin, a 
fat derived hormone/cytokine is involved in cell energy regulation, glucose 
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metabolism and modulation of immune responses221. We evaluated the role of 
adiponectin in a DSS model of colitis. Adiponectin or LacZ (control gene) was 
overexpressed using an adenoviral construct43. The adiponectin treatment group 
has a significantly better outcome as assessed by clinical and histologic criteria. 
We chose an innate immunity mouse model of IBD since adiponectin has 
structural and functional similarities to complement. The first evidence for a 
protective role came from the Nishihara group42. They demonstrated that 
adiponectin treatment protects adiponectin KO mice from DSS colitis. 
Interestingly no benefit was noted in TNBS colitis. Since the latter model is more 
dependent on T cells, one may speculate that adiponectin has greater influence 
on innate immunity. This is also supported by the fact that T cells from either wild 
type of adiponectin KO mice produce similar amounts of IL-6, IL-17, TNF-α and 
IFNγ upon stimulation with anti CD3/CD28 222. In vitro studies revealed that 
adiponectin suppressed expression of IL-8 in the human HT-29 epithelial cell line 
42. Surprisingly, others223 found that the adiponectin promotes and potentiates IL-
8 in the same cell line. Nevertheless this activity was elicited by globular 
adiponectin at doses between 1 and 5μg/ml. Adiponectin circulates mostly as 
HMW 58 at similar concentrations and it is unlikely that globular form will be 
generated in vivo at the same levels. We prospectively evaluated adiponectin 
levels in two cohorts of Crohn's Disease patients and healthy volunteers 
respectively. There was no   difference between total adiponectin but we 
detected significantly lower values in the HMW fraction224. The differences 
between controls and IBD patients were not related to common adiponectin SNP 
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mutations. Nevertheless, when Crohn’s Disease patients were analyzed, a third 
of those with A>G 11426 in the promoter region had fistulizing or stricturing 
disease while less than 15% had this phenotype in the absence of mutation. This 
mutation lies within a PPARγ response element and may be responsible for the 
induced rather than the constitutive adiponectin level. In addition, inflammatory 
cytokines and cellular stress can modulate HMW secretion225. Based on our 
studies and prior evidence we believe that TNFα, angiotensin and osteopontin 
play an important role. Altered receptor expression can further modulate the 
effects of adiponectin. Overall, no significant changes in adiponectin receptors 
were seen in our mouse model. This may be because we analyzed the entire 
colonic specimen rather specific cell fraction. Using in-vitro bone marrow derived 
dendritic cells, we determined that LPS downregulated AdipoR1 and AdipoR2. 
This may represent a state of adiponectin resistance that can be reversed by 
PPARγ and retinoic acid agonists. We also correlated serum HMW adiponectin 
and colonic adiponectin receptors expression with specific IBD subgroups. 
Crohn's Disease patients in subsets 2(↓PC1↓PC2) and 3 (↑PC2) had lower 
circulating HMW adiponectin and intestinal receptor mRNA expression. 
             In sharp contrast to our findings, Fantuzzi et al, showed that adiponectin 
KO mice were protected from DSS and TNBS colitis, and adiponectin treatment 
induces inflammation41. In addition, colonic explants from treated mice released 
more IL-6. Differences in adiponectin KO mice have been invoked since only the 
former group showed high basal TNF-α production and increased susceptibility to 
LPS. Several recent studies confirm that adiponectin effectively blocks LPS 
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induced release of pro-inflammatory cytokines and thus support an anti-
inflammatory role138,226-228. Moreover, when the latter group investigated the 
outcome of colitis in IL-10 KO and adiponectin/IL-10 double KO no differences 
were seen 222. It was concluded that adiponectin does not play a role in this 
colitis model. In accordance with our preliminary experiments, and published 
data 134,229 we believe that IL-10 production is paramount for the anti-
inflammatory role of adiponectin in colitis. Therefore, the results seen in IL-10 KO 
mice are expected. Furthermore, if adiponectin promotes inflammation the 
double KO (adiponectin/IL-10) mice should have had increased morbidity and 
mortality. Adiponectin induced IL-10 may thus promote alternative activation of 
macrophages and promote resolution of chronic inflammation. Adipose tissue 
macrophages from lean mice express many genes characteristic of M2 
(alternatively activated phenotype) macrophages230, including Ym1, arginase 1, 
and IL-10. Diet-induced obesity decreases expression of these genes while 
increasing expression of those encoding TNF-α and Nos2 (nitric oxide synthase) 
that are characteristic of M1 (classically activated) macrophages231. Furthermore, 
AMPK, the kinase that translates adiponectin signaling, suppresses 
proinflammatory responses and promotes macrophage polarization to an anti-
inflammatory, M2 functional phenotype 232. Our findings in the DSS model of 
colitis were consistent with reduced gut macrophage infiltration and increased 
markers of M2 polarization. The in vivo events leading to IL10 secretion are not 
established. Upregulation of adiponectin receptors on antigen presenting cells, 
as seen in our in vitro study, or increased phagocytosis of apoptotic bodies 
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through specific interactions between adiponectin and thrombospondin are 
attractive hypotheses. Osmotin a plant derived adiponectin receptor agonist 233 
ameliorated DSS colitis and promoted IL10 secretion. Since Osmotin is 
structurally different, a direct effect rather than interaction with other inflammatory 
mediators is suggested.  Angiotensin acts as a pro-inflammatory cytokine and 
promotes development of colitis 81,234. Both gut epithelium and surrounding 
mesenteric fat can convert angiotensinogen to active angiotensin. We have 
consistently seen a negative correlation between angiotensin/angiotensin 
receptor 1 and adiponectin levels. Thus, modulation of fat derived adipokines by 
adiponectin contributes to the anti-inflammatory milieu during colitis.  
                 Environmental factors play an important role in Inflammatory Bowel 
Diseases235. The strongest association has been seen with cigarette smoke 
exposure 236-237.  Cigarette smoke contains a mixture of dioxin-like compounds, 
which activate the aryl hydrocarbon receptor (AhR) pathway. In its inactive state, 
the AHR exists as a multiprotein complex. Following agonist binding, the AHR 
translocates to the nucleus, dimerizes with its DNA binding partner ARNT and 
binds specific DNA sequences (DREs). AHR activation by endogenous 
agonist(s) is likely transient and physiological. Activation by synthetic long-lived 
exogenous agonists, as TCDD is inappropriately sustained and hence, 
pathophysiological. Candidate endogenous AHR agonists include indole and 
tryptophan metabolites 89,238. Indole is produced from tryptophan by the 
commensal bacteria and inhibits NF-κB signaling, tight-junction resistance and 
expression of inflammatory cytokines in intestinal cells239. We have found that 
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AHR expression appears to be largely restricted to enterocytes in human patients 
240. Thus, we speculate that the normal, physiological role of the AHR within the 
intestine is to sense the presence of the bacterially generated AHR agonists and 
regulate physiological inflammatory responses. Our experiments in AhR -/-, 
heterozygote and wild type mice yielded different phenotypes240. The AhR 
heterozygote was protected from colonic inflammation. Both AhR -/- and wild type 
mice had severe colitis but the former exhibited increased mortality. We 
proposed that complete absence of AhR may alter gut permeability and promote 
inflammation. The results in AhR -/- were consistent with observations that these 
mice have a heightened response to LPS stimulation. In comparison to wild type 
mice, the heterozygote mice had a shift toward the Treg phenotype. Specifically, 
we observed an increased intestinal FoxP3 expression at the expense of RORγ. 
Thus, AhR ligands (endogenous and dietary) can alter the Treg/Th17 balance241. 
Consistent with this polarization we noted increased IL10 production and 
decreased IL17 and TNFα in the colon of AhR heterozygote mice. Furthermore 
these mice had lower levels of MCP-1 and colonic macrophages. The observed 
effects were related to the AhR level of expression.  Similar conclusions can be 
draw from our analysis of Crohn's Disease and healthy volunteers. We have 
assessed AhR activation by determining the expression of its nuclear target 
CypA1. In normal subjects, there was minimal AhR activation restricted to the 
epithelial layer. This likely reflects the AhR role in gut permeability. Treatment of 
the human epithelial colonic line CaCO2 with an AhR antagonist significantly 
decreased the transepithelial electrical resistance while the long acting agonist, 
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TCDD restored it. Analysis of intestinal biopsies from IBD-Crohn's Disease 
patients have showed decreased epithelial expression and significant 
upregulation in lamina propria mononuclear cells. The upregulation of AhR 
expression correlated with an AhR responsive inflammatory cytokine, IL8. 
Although CypA1 was used as a read-out of AhR activation, interactions with NF-
KB (RelA and RelB) through a non-canonical pathway are likely important90. It is 
generally accepted that AhR and NF-kB negatively regulate each other. 
Therefore it is conceivable that increased epithelial AhR expression reduces NF-
kB and thus alters gut permeability. Since AhR -/-, mice have developmental 
defects we explored the effects of pharmacological blockade on DSS colitis in 
wild type mice. A similar outcome was noted. On the other hand, TCDD, a long 
acting agonist protects mice from DSS colitis. Preliminary studies in our 
laboratory confirmed these findings in mild (1.5% DSS) but not severe forms of 
colitis (3.5% DSS).  
                We have previously shown that AhR agonists (TCDD, PCB77) promote 
obesity and adipose tissue inflammation84. These lipophilic compounds are 
widely distributed in the environment, and preferentially accumulate into the 
visceral fat. Furthermore, we showed that PCB77 treatment promotes 
perivascular inflammation and intraabdominal ectopic fat deposition in a mouse 
model of aortic aneurysm (manuscript submitted). Therefore, we investigated the 
profile of anti-inflammatory (adiponectin) and pro-inflammatory (angiotensin) 
during DSS colitis in mice with low (AhR-/+) and normal AhR expression. AhR 
heterozygote mice (AhR-/+) exhibited a significant downregulation of angiotensin 
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precursor, angiotensin receptor AT1a and angiotensin converting enzyme (ACE) 
correlated with a positive clinical outcome. Furthermore, serum and tissue levels 
of adiponectin were elevated. The link between AhR, adipokines, inflammation 
and obesity is of high relevance since an important number of IBD patients are 
either obese or at risk of metabolic syndrome. Recent associations between IBD 
(Crohn's Disease and Ulcerative Colitis) and BMI (body mass index) could reflect 
the effect of AhR on disease phenotype 36,242.  
             In summary, we provide evidence of unique immune phenotypes in IBD 
with relevance for clinical practice. Furthermore, the signature biomarkers for 
Crohn's Disease may serve as a guide to patient selection in clinical trials and 
development of relevant animal models. Our current studies link adipose tissue 
derived cytokines with the xenobiotic pathway, and offers a framework to further 
evaluate the role of environmental cues in IBD development. We propose a 
disease model whereby genetic and environmental factors (AhR ligands) alter 
gut barrier by acting on targets such as NF-kB and pIgR. This leads to bacterial 
translocation with specific patterns of inflammation  related to the patient's 
immune phenotype (biomarker subset). Increased visceral adiposity (diet, AhR 
mediated) and accumulation of lipophilic AhR ligands induces a second wave of 
inflammatory mediators. Low adiponectin and activation of the renin angiotensin 
system within the gut and surrounding adipose tissue are expected to promote 
an inflammatory milieu. Ultimately, these events can promote M1 macrophage 
and Th1/Th17 polarization responsible for the chronic relapsing course of IBD. 
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Future Directions 
          Investigation of NF-kB related targets relevant for innate mucosal 
immunity, allowed us to identify the pIgR/IgA system as a novel pathway in 
patients with Inflammatory Bowel Diseases. More importantly, it points to the fact 
that a pathway approach is likely to yield results in the quest for disease 
biomarkers. The current five-biomarker set will be expanded to include 
adipokines, adipokine receptors and components of the aryl hydrocarbon 
pathway. Selection of specific targets will be guided by in vitro studies. I am 
particularly interested in regulation of TLR signaling by adiponectin and 
downstream interactions with canonical and alternative NF-kB pathways. 
Ultimately, the utility of these biomarkers have to be tested in prospective clinical 
trials. Inflammatory Bowel Diseases naïve to immunomodulatory therapies will be 
randomized to treatment based on the biomarker subsets. The clinical response 
and mucosal healing will be assessed and correlated with subset allocation. 
Another important question that may be answered is whether these subsets are 
stable or they can be altered by successful immune therapies. These finding may 
have significant importance on early choice of treatments. Analysis of biomarker 
expression in the gut mucosa requires an invasive endoscopic procedure. On the 
other hand sampling of oral mucosa would be easily performed. Therefore, we 
would like to investigate the correlation of proposed gene targets in the gut and 
oral mucosa and thus offer a better modality of immune-phenotyping the IBD 
patients. 
           A significant number of IBD patients are overweight. Our results are in line 
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with studies that link adiponectin to innate immunity response and macrophage 
function. We propose that signaling downstream of adiponectin receptors alter 
the balance between M1 (classical) and M2 (alternative) macrophages. Targeted 
deletion of macrophage adiponectin receptors, and/or chimeric mouse models 
using macrophage transfer from receptor KO mice will be investigated in acute 
and chronic models of colitis. Adiponectin replacement is not considered a 
feasible treatment modality. Alternative options include: 1) synthetic or natural 
agonists; 2) increased receptor expression. We have discovered that the plant 
agonist Osmotin can have protective effects during colitis. Further studies will 
test its value in the context of impaired adiponectin activity: 1) selective 
adiponectin receptor deficiency; 2) adiponectin deficiency (KO mouse);3) 
acquired adiponectin deficiency through diet induced obesity.  
           Although the role of environment in Inflammatory Bowel Diseases is 
widely accepted, until recently, no specific pathway was identified. Our study 
identified for the first time that the aryl hydrocarbon might play a role in the 
development of IBD. The main target of the AhR signaling in both human and 
experimental IBD has not been elucidated. We will investigate the consequences 
of AhR deletion in gut epithelial cells as immune cells. Moreover, T cell transfer 
from mouse donor exposed to individual AhR ligands (agonists and antagonists) 
as well as complex mixtures (cigarette smoke) will allow dissection of more "real-
life" scenarios. We are hopeful that our research endeavors will create a better 
understanding of the link between environment, metabolism and immunity. 
Copyright  @ Razvan I Arsenescu 
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